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ABSTRACT
Infection Models of Intracellular Staphylococcus aureus and the Impact
of Interleukin 12 on Macrophage Killing Activity
Therwa Hamza
Staphylococcus aureus (S. aureus) is the predominant cause of bone and joint
infections worldwide. These infections may lead to severe bone and joint destruction and
high mortality. Treatment of bone infections frequently requires long-term hospitalization
for repeated debridement and prolonged antibiotic treatment. Bacteria including S. aureus,
however, are often surprisingly successful in overcoming both host defense mechanisms
and antibiotic treatments resulting in chronic and recurrent bone infections. Indeed, a
high rate of recurrence or relapse of bone infections has been reported where ~17% of
infections related to traumatic extremity injuries recur or relapse. One thought is that
bacteria like S. aureus used to elude host defenses and antibiotic treatments are able to
“hide” themselves intracellularly within host cells.
S. aureus has conventionally been considered as an extracellular pathogen, but
there is growing evidence showing that it can survive intracellularly within host cells.
Once internalized into host cells, S. aureus may elicit a pro-inflammatory response often
characterized by the secretion of interleukin 1β (IL-1β), IL-6, IL-12p70 (IL-12), and
tumor necrosis factor-α (TNF-α) among other cytokines. Production of pro-inflammatory
cytokines from infected osteoblasts may disrupt the balance of the immune system
thereby leading to uncontrolled inflammation and bone destruction. On the other hand,
IL-12 is released primarily by antigen-presenting cells and acts as a link between innate

and acquired immunities by inducing the differentiation of the T helper 1 (Th1)
phenotype and the release of interferon gamma (IFN-γ) from activated T-cells as well as
natural killer cells. T-cell-derived IFN-γ is considered crucial to the activation of
macrophages, the ultimate effector cells in host defense against intracellular infection.
Studies have shown that both IL-12 and IFN-γ are up-regulated in infection models of
other bacteria, parasites, and viruses but little is known about how they may contribute to
the outcome of infection.
The overall goal of this dissertation is to develop in vitro and in vivo infection
models of intracellular S. aureus that can aid in understanding the pathogenesis of
chronic and recurrent infections and to develop effective immunotherapy regimens to
prevent or treat such infections. This dissertation starts with an overall literature review
in Chapter 1 about the bacterium S. aureus, implant-associated infection, and finally IL12 as a potential therapeutic agent against infections. Chapter 2 establishes and
compares two S. aureus infection models utilizing a non-phagocytic cell (osteoblast) and
a phagocyte (macrophage) and the corresponding cellular responses of each cell type
upon infection. In Chapter 3, S. aureus within osteoblasts is used to infect an open
femur fracture rat model. We have presented the first direct in vivo evidence that
intracellular S. aureus could be sufficient to induce bone infection in animals and
intracellular S. aureus could play an important role in the pathogenesis of S. aureus
infections. Finally, a potential approach using IL-12 as a therapeutic agent to improve
macrophage killing activities against intracellular S. aureus is investigated in Chapter 4.
Keywords: osteomyelitis, Staphylococcus aureus, infection, interleukin 12, cytokine,
osteoblast, macrophage, rat, intracellular S. aureus.
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SPECIFIC AIMS
For decades, S. aureus has been recognized as one of the most important leading
cause of hospital- and community-acquired infections worldwide. Controlling S. aureus
infections, especially chronic and recurrent infections, is a growing clinical challenge,
and a better understanding of S. aureus pathogenesis and development of new therapeutic
strategies are of importance. To achieve this long-term goal, my project has three specific
aims:

1) Establish and compare in vitro S. aureus infection models using phagocytic
(macrophage) and non-phagocytic cells (osteoblast)
2) Determine whether intracellular S. aureus can induce bone infection in vivo
3) Introduce IL-12 as a therapeutic agent to improve the killing efficacy of
macrophages against intracellular S. aureus

ix

CHAPTER 1

Literature Review
1.1

Staphylococcus aureus

1.1.1.

Biology and Virulence Factors
Staphylococcus aureus (S. aureus) is a Gram-positive spherical bacterium,

between 0.5 to 1.7 μm in diameter, non-motile, facultative anaerobic, catalase and
coagulase positive that is able to induce ß-haemolysis [1]. Traditionally, S. aureus is
considered to be an extracellular pathogen [2, 3], but increasing evidence indicates that S.
aureus might be a facultative intracellular pathogen [4-9]. The species name “aureus”,
which means “golden” in Latin, is due to the yellow-golden color of the colonies. The
color is imparted by carotenoid pigments that support the bacteria in the prevention of
oxidant killing by phagocytes. Approximately, 20-30% of human beings are persistently
colonized with S. aureus in the nose, skin, mucosa, the axilla region, or gastrointestinal
tract [10].
The remarkable success of S. aureus as a pathogen is due to the expression of a
wide array of virulence factors including a capsule as well as surface-exposed and
secreted proteins [11, 12]. A schematic representation of S. aureus virulence factors is
illustrated in Figure 1. Protein A is the hallmark of S. aureus which is able to bind
immunoglobulins through their fragment crystallizable region (Fc) thereby hampering Fc
receptor-mediated opsonophagocytosis [13, 14]. Protein A can also induce T-cellindependent proliferation and apoptosis of B cells [15]. Coagulase is an extracellular
protein that results in clotting of the blood that might protect the bacterium from
1

Figure 1. Pathogenic factors of Staphylococcus aureus, with structural and secreted
products both playing roles as virulence factors.
phagocytic uptake by immune cells [16]. The clumping factor A and B bind serum
fibrin/fibrinogen and reduce the activity of phagocytic immune cells [17]. The collagenbinding and fibronectin-binding proteins support the adhesion of S. aureus to connective
tissue, cartilage, and extracellular matrix [18, 19]. Enterotoxin B and toxic-shocksyndrome-toxin 1 (TSST-1) are bacterial superantigens that bind major histocompatibility
complex

II

(MHC

II)

complexes

on

antigen-presenting

cells

leading

to

immunosuppression [20-22]. The α-toxin is the best-characterized and more potent
cytotoxin of S. aureus. It binds to cell surface receptors and lipid bilayers on host cells
and forms pores that eventually cause cell death [23, 24].

2

1.1.2. Intracellular S. aureus
S. aureus has long been considered an extracellular pathogen [5]. However, many
studies have demonstrated its remarkable ability to survive and replicate intracellularly
[25]. The ability of S. aureus to escape host immunity and then establish a cell-niche are
actually crucial steps in its pathogenesis [3, 5].
S. aureus possesses several cell-surface adhesion molecules that facilitate its
binding to extracellular matrix components. Binding involves a family of adhesins known
as microbial surface components recognizing adhesive matrix molecules (MSCRAMMs).
MSCRAMMs recognize proteins such as fibronectin, collagen, and fibrinogen to mediate
adherence of S. aureus to epithelium, endothelium, bone, and biomaterials coated with
host proteins [26]. Among all MSCRAMMs, fibronectin-binding proteins (FnBPs) are the
most critical for adherence and internalization of S. aureus. The schematic representation
in Figure 2 shows S. aureus attached to α5β1-integrins on the surface of a non-phagocytic
cells, such as epithelial cells, endothelial cells, or osteoblasts, via fibronectin fibrils that
are bound to FnBP (attachment). The host cell integrins are associated with myosin
bound tensins, and by contraction of the myosin, the bacteria are transported toward the
cell center. The uptake is performed by tensin-mediated actin reorganization [27, 28].
Currently, the mechanisms allowing for the intracellular survival of S. aureus
have not yet been fully understood [5, 29]. In some non-phagocytic cells, S. aureus is
able to escape from phagolysosomes and multiply in the cytosol. It also leads to the death
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Figure 2. Schematic diagram of some of the signaling events involved in invasion of
‘non-professional phagocytic’ host cells by S. aureus. Adapted from Wright and Nair
(28).
of these cells by apoptosis [30-32]. In contrast, in phagocytic cells, S. aureus seems to
remain trapped within vacuoles [33, 34] where its multiplication is slowed down but not
impaired by the acidic pH [35]. S. aureus is also known to produce enzyme degrading
oxidant species (catalase, hydroperoxide reductase, and superoxide dismutase) [36],
which may contribute to protecting it intracellularly.
Within the cell, S. aureus can switch to a phenotype known as small-colony
variants (SCVs) that provides several advantages for its intracellular survival, among
which are smaller colony size and reduced growth rate [37-39, 5]. SCVs demonstrate a
number of characteristics that are different from S. aureus and are linked to interruption
of electron transport [40]; they also present an altered antibiotic sensitivity [38], being
most notably resistant to aminoglycosides [41]. SCVs are auxotrophic and can revert to
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normal growth and morphology in the presence of menadione and hemin, thiamine, or
CO2-rich culture medium [42].

1.1.3.

Host Immune Response
Normally, macrophages and other leukocytes in the host eliminate invading

bacteria by a process called phagocytosis. Bacteria are engulfed into phagosomes and
eventually fuse with lysosomes forming a phagolysosome where the microorganisms are
destined for destruction. There, the bacteria are exposed to a number of toxic chemicals
and enzymatic agents, some of which are reactive oxidative species such as superoxide
anions and hydrogen peroxide, acidic pH, and degradative proteases. The pathogenicity
of S. aureus is mainly mediated by a variety of secreted enzymes, adhesins, immunomodulating proteins, and the presence of cell wall compounds [43]. Recognition of S.
aureus components by innate immune cells is the first step of host defense. Toll-like
receptors (TLRs) are a class of receptors that recognize pathogen-associated molecular
patterns (PAMPs) such as LPS, peptidoglycan, and lipoprotein [44, 45]. TLRs that are
involved in the recognition of S. aureus include TLR2 which binds bacterial
peptidoglycan and TLR9 which binds bacterial CpG DNA. Triggering of TLR signaling
after pathogen recognition leads to the activation of transcription factors that induce
transcription of genes coding for various proteins including cytokines and inflammatory
mediators [46]. This process results in a massive invasion of immune cells to the site of
infection. Several studies using knockout mice have shown that TLRs play a critical role
in the innate immune response to Staphylococcal infections as mice deficient in the
expression of myeloid differentiation factor 88 (MyD88), a cytoplasmic adaptor molecule
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essential for the signaling of IL-1R/TLR family, are highly susceptible to this pathogen
[47].
An effective immune response against S. aureus involves polymorphonuclear cell
(PMN) recruitment such as neutrophils [48, 49]. The importance of neutrophils in host
defense against S. aureus infection has been demonstrated by recurrent S. aureus
infections in patients with chronic granulomatous disease, who have a defect in the
NADPH oxidase and respiratory burst [48, 50].

1.1.4.

Treatment for S. aureus Infections
Despite increasing knowledge on this bacterium, it is still difficult to prevent or

effectively treat Staphylococcal infections in many cases. Developing new therapeutic
strategies (including antibiotic and alternative therapies) as well as prophylaxis strategies,
which are important for patients before invasive medical procedures, is an essential topic
in research [51-54].
Treatment of S. aureus infections is commonly done using antibiotics, especially
β-lactams [55]. The hospital-acquired strain of methicillin-resistant S. aureus can be
susceptible to rifampicin, fusidic acid, and co-trimoxazole but they are rarely used
because this strain can easily acquire resistance [56].
Cationic antimicrobial peptides (CAMPs) such as defensins, cathelicidin, and
thrombocidins are positively charged (+2 to +7) amphipathic molecules with antibacterial
properties [57-59]. Produced by the innate immune system, they protect the skin and
epithelia from bacterial invasion [60].
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There is still a problem with the introduction of an efficient vaccine in the
prevention of infections caused by S. aureus. This can be associated with the fact that,
throughout its life, a human organism is in contact with this bacterium as many people
are constant or transient carriers of S. aureus on the mucus of the nasal or oral cavity.
Earlier, the whole bacterial cell was used as an antigen, but recent research is aimed at
obtaining antibodies against specific virulence factors such as adhesins, toxins, or
invasins [61].
FnBPs are responsible for adherence of S. aureus to and subsequent
internalization by phagocytes. Intramuscular application of a recombinant fragment of the
fibronectin-binding domain (rFnBF), which potentially inhibits the entrance of S. aureus
to host cells, counteracted the formation of abscesses in guinea pigs. The protective effect
was dose-dependent and increased the efficacy of preventive treatment if applied
simultaneously with cefazolin. The efficacy of this method relies on competition in the
adhesion of exogenic S. aureus rFnBF with FnBP, which causes infection [62].

1.2

Implant-Associated Infections and Osteomyelitis

1.2.1.

General Concepts
Bone turnover is a highly regulated process. New bone is formed by osteoblasts,

which are cells of mesenchymal lineage derived from osteoprogenitor cells located in the
periosteum or bone marrow. Osteoblasts form new bone matrix, called osteoid, which is
later mineralized as osteoblasts mature. When osteoblasts become surrounded by
mineralized matrix, they become osteocytes. Old or damaged bone is resorbed by
osteoclasts via a process called bone resorption. Osteoclasts are large multinucleated cells
7

of hematopoietic lineage derived from the fusion of monocytes and macrophages.
Osteoclasts are activated and recruited to sites of microfracture by factors such as
macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor
κβ ligand (RANKL). The balance in osteoblast and osteoclast activities is critical for
healthy bone environment and successful implant procedures.
Orthopaedic implants are commonly used in treating patients with pain and
compromised mobility or for fracture fixation. The risk of infection is increased by the
presence of foreign materials in the body. The most commonly cultured pathogens
isolated from prosthetic implant-associated infections are S. epidermidis (30 to 43%) and
S. aureus (12 to 23%), followed by mixed bacterial flora (10 to 11%), streptococci (9 to
10%), Gram-negative bacilli (3 to 6%), enterococci (3 to 7%), and anaerobes (2 to 4%)
[63]. Recently, S. aureus SCVs, which have a slower metabolism, do not produce toxins,
and are more resistant to antibiotics, have been isolated from implant-associated
infections and represent a risk factor for treatment failure, and persistence and recurrence
of infection [64].
Implant-associated infections occur by bacterial contamination of the surgical site
during surgery or immediately after, or they result from haematogenous spreading from
distinct infections in the nose or on the skin. The resulting infection of the bone and soft
tissue is called osteomyelitis, which is an inflammatory process characterized by massive
bone destruction, or osteolysis (5). The disease can be acute or chronic with periodic
recurrence [65, 66]. Chronic osteomyelitis is usually defined as osteomyelitis occurring
in a patient who cannot be cured by medical means within six weeks [67]. The hallmarks

8

of chronic osteomyelitis include the presence of pus, persisting microorganisms, lowgrade inflammation, and dead bone without a blood supply (sequestra) [68].
There are three types of osteomyelitis: haematogenous osteomyelitis which is
commonly found in children and in elderly patients, osteomyelitis secondary to diabetic
foot infection, and osteomyelitis caused by local spread from an adjacent infection after
trauma, surgery, or joint replacement, while the incidence of the latter is the highest [5].

1.2.2.

Pathogenesis
Staphylococci have a strong ability to adhere to plastic surfaces, a fact that has

been used in basic in vitro assays. However, during colonization on medical devices, the
additional interaction of MSCRAMMs and host proteins most likely cause a stronger
attachment (61, 69]. This bacterial colonization forms what is called a biofilm, which is a
microbial community covered by a thin three-dimensional structure matrix [70, 71]. The
host immune system responds to foreign bodies with a localized inflammation leading
first to the formation of a capsule-like membrane of fibrinogen, fibronectin, and collagen
on the surface [72]. Extracellular proteins such as fibronectin and fibrinogen mediate
bacterial adhesion to medical devices and host tissue. The localized inflammation causes
a secondary phenomenon known as “frustrated phagocytosis”, which results from
granulocyte contact with the foreign body and causes a functional granulocyte defect with
reduced oxygen burst and chemotaxis in the presence of foreign bodies (Figure 3). This
process may be partly responsible for the high susceptibility of implants to infections [74].

9

Figure 3. Pathogenesis of implant-associated infection. Adapted from Biomaterials
(Biomaterials Science: An Introduction to Materials in Medicine, 2nd edition).
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1.2.3.

Therapy
The goal of implant-associated infection therapy is a long-term application and

functional joint and is achieved by elimination of the infection. But, implant-associated
infections are difficult to treat due to lack of microcirculation, which is crucial for host
defense and for the delivery of antibiotics. Five treatment approaches utilizing
appropriate surgical treatment and antimicrobial therapy are available. (I) Long-term
antimicrobial therapy alone does not eradicate the infection. Additionally, clinical
symptoms re-appear during or after antimicrobial breaks. (II) Debridement with retention
of the prosthesis means removal of tissue around a stable implant for patients with an
early postoperative or acute haematogenous infection (<3 weeks). Furthermore, an agent
with activity against biofilm bacteria should be available. (III) and (IV) One- or two-stage
revision includes removal of all devices, debridement, and replacement of a new
prosthesis during the same procedure or after a period of time, respectively. (V) Finally,
resection is defined as permanent removal and debridement without replacement [74, 63].

Surgical intervention as well as antibiotic therapy using cephalosporins and
penicillins remains the most effective means of treatment for osteomyelitis [75]. However,
osteomyelitis cases caused by S. aureus are especially chronic in nature and recalcitrant
to therapy. In addition, the effectiveness of traditional antibacterial agents is becoming
increasingly limited as the incidence of methicillin-resistant S. aureus (MRSA) has
increased sharply in recent years. The wide array of virulence factors in S. aureus,
including secreted products for host damage and immune evasion, coupled with its ability
to invade and reside inside host cells using cell surface adherence factors, can protect
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these bacteria from host defense mechanisms and antibiotics which can account for the
persistence of disease despite what may be considered adequate surgical and antibiotic
management [76].

1.3

Interleukin 12: a Key Immunoregulatory Cytokine in Infection Applications
It is well-established that CD4+ T helper (Th) cells can be divided, besides T

regulatory and Th17, into two major subsets: Th1 and Th2, based on their patterns of
cytokine production. Th1 cells mainly secret interleukin 2 (IL-2), IFN-γ, and IL-12,
whereas Th2 cells secret IL-4, IL-5, and IL-10 [77]. Functionally, Th1 cells
predominantly promote cell-mediated immunity and help in clearance of intracellular
pathogens, whereas Th2 cells are responsible for humoral immunity protecting against
extracellular invaders. The balance between IL-12, favoring Th1 responses, and IL-4,
favoring Th2 responses, determines the early preference expressed in the immune
response.
IL-12 has multiple biological functions; importantly, it bridges the early
nonspecific innate resistance and subsequent antigen-specific adaptive immunity [78]. IL12 was first identified as a product of Epstein-Barr virus (EBV)-transformed human B
cell lines. IL-12 was previously known as T-cell differentiation factor (TCDF), or natural
killer cell stimulatory factor (NKSF). IL-12 was used to be the only known heterodimeric
cytokine, but it is now part of a family consisting of several other members including IL23, IL-27, and the recently identified IL-35. These new molecules have been found to
play distinct cellular and functional roles in Th1 development [79].

12

1.3.1 IL-12 Molecular Structure
IL-12 is a key immunoregulatory cytokine [78, 80, 81] with a molecular weight of
70 kDa; it is composed of two covalently-linked subunits, IL-12p35 (35 kDa) and IL12p40 (40 kDa), each of which is expressed on different chromosomes. The sequence of
the p35 gene is homologous similar to that of IL-6 and granulocyte-colony stimulating
factor [82]. The sequence of the p40 chain has a homology to the extracellular domain of
IL-6 receptor (IL-6R) α-chain and the ciliary neurotropic factor [83]. This homology
explains some of the redundant actions applied by these cytokines.
Although p35 transcripts are found in many cell types, free p35 is not secreted
without the p40 subunit. IL-12p40 is produced predominantly by activated monocytes,
macrophages (MФs), neutrophils, and dendritic cells (DCs). It has been suggested that in
mice, but not in humans, IL-12p40 homodimers antagonize IL-12p70 activity by binding
to the β1 subunit of the IL-12 receptor [84-86]. Also, IL-12p40 has been shown to act as
a chemoattractant for MФs and promotes the migration of stimulated dendritic cells [87].
The p40 subunit is associated with several pathogenic inflammatory responses such as
silicosis, graft rejection, and asthma, but it is also found to be protective in a
mycobacterial infection model [87].

1.3.2

IL-12 Receptor and Signaling Pathway
The biological activities of IL-12 are mediated via binding to a membrane

receptor complex which is also composed of two subunits: IL-12R β1 and IL-12R β2.
Both of the subunits are members of the class I cytokine receptor family, which includes
IL-6, IL-11, and leukocyte inhibitory factor related to glycoprotein gp130 [88, 89]. There
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Figure 4. IL-12 signaling pathway. IL-12 activates the Jak/STAT pathway. Following
binding of IL-12p40 and IL-12p35 to IL-12R β1 and IL-12R β2, respectively, Jak-2 and
Tyk-2 get transphosphorylated. Phosphorylated IL-12R β2 binds to STAT4 which will
then dimerize with another STAT4 molecule. STAT4 homodimers translocate to the
nucleus and promote IFN-γ gene transcription. T-bet is another transcription factor that
plays a role in Th1 development and IFN-γ production. The IL-12 and IFN-γ produced
induce the activity and proliferation of MФs, NK cells, and T-cells, which also secrete
IL-12. Modified from [97]. Reprinted from Cytokine & Growth Factor Rev., 14(5),
Watford, W.T.; Moriguchi, M.; Morinobu, A.; O'Shea, J.J. The biology of IL-12:
coordinating innate and adaptive immune responses, 361-368, Copyright (2003), with
permission from Elsevier.

is a high level of conservation, with a 68% amino acid sequence homology, between
mouse and human IL-12R β2 proteins, and a 54% sequence identity homology between
the mouse and human IL-12R β1 [88]. Both receptor chains are required to mediate
maximal signaling; however, the two chains have independent roles. IL-12R β1 is
required for high-affinity binding to the IL-12p40 subunit and is associated with the
14

Janus kinase (Jak) family member Tyk-2. The IL-12R β2 chain mediates signal
transduction via three tyrosine residues that act as a docking site for STAT4; it is
associated with Jak-2 (Figure 4). IL-12R β2 recognizes either the heterodimer IL-12 or
IL-12p35 subunit and is expressed, not on naive T-cells, at low levels after T-cell
receptor stimulation. Expression of this receptor subunit is critically influenced by IL-12
and type 1 IFNs [81]. The initial expression of functional IL-12Rs is further enhanced
when IL-12 is present at the time of priming, working as a positive feedback loop
regulator [90].
The signaling pathway of IL-12 is described in Figure 4. On binding of IL-12 to
the IL-12R complex, activation of Jak kinases (Tyk-2 and Jak-2) occurs, leading to
phosphorylation of the receptor, which becomes a binding site for STAT4 proteins that
are rapidly recruited to the receptor and phosphorylated on their tyrosine residues by the
Jak

kinases.

Tyrosine

phosphorylation

of

STAT4

proteins

induces

their

homodimerization and translocation to the nucleus where they bind to specific sequences
and regulate gene transcription (Figure 4). In Th1 and NK cells, IL-12 mainly induces
STAT4 activation. In addition, STAT1, STAT3, and STAT5 can also be activated by IL12 signaling [89, 91]. Studies have shown that IFN-γ increases the transcription factor Tbet activity, which was originally shown to be induced in Th1 cells [92]. T-bet response
to IFN-γ leads to the up-regulation of IL-12R β2 surface expression and allows for Th1
cell responsiveness to IL-12 [92, 93]. More recent studies showed that T-bet negatively
regulates GATA-3 expression, the main regulator of Th2 cell axis [94]. In contrast, the
Th2 cytokine IL-4 reduces IL-12R β2 expression and thus leaves Th2 cells nonresponsive [95]. The opposite effects of IFN-γ and IL-4 on IL-12R β2 expression may
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contribute to the commitment of Th1/Th2 differentiation. Priming of macrophages with
IFN-γ increases cellular responsiveness to inflammatory stimuli, including IFN-γ itself,
which activates direct microbicidal functions including the production of reactive oxygen
species and TNF-α and promotes the Ag processing and presentation capacities of
macrophages. Also, IFN-γ plays a role in the regulation of T-cell proliferation and
activity [96].

1.3.3

IL-12 Family Members
The IL-12 family has expanded recently to include members including IL-23, IL-

27, and IL-35. IL-12 and these new family members play critical roles in Th1 cell
development [80, 98]. Table 1 summarizes the structure and biological properties of these
major IL-12 family members.

A. Interleukin 23
IL-23 is a proinflammatory cytokine that is closely related to IL-12 in structure;
they both share the p40 subunit that is able to build a disulfide bridge complex with the
p19 subunit to form the biologically active molecule. The p40-p19 complex is mainly
secreted by activated intestinal antigen presenting cells, such as DCs and monocytes [98].
Similar to IL-12 signaling, IL-12R β1is required for high affinity binding to p40, whereas
IL-23R has a cytoplasmic STAT4 binding domain for signal transduction. However,
STAT3/STAT4 heterodimers in IL-23 instead of STAT4 homodimers in IL-12 are
translocated to the nucleus to induce specific gene expression [99].
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Table 1. The IL-12 cytokine family; structural and biological characteristics.

The main role of IL-23 involves the stimulation of Th17 cells to produce IL-17
[79] and it induces the proliferation of memory T-cells [100]. Unlike IL-12, IL-23 does
not induce significant production of IFN-γ, and in the absence of IL-23, IFN-γ production
and Th1 differentiation are still found to be normal [98].
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B. Interleukin 27
IL-27 is another heterodimeric cytokine composed of the p28 subunit and the p40related protein Epstein-Barr virus-induced gene 3 (EBi3). IL-27 activities are driven via
one receptor that was described recently with some homology to gp130, known as TCCR
or WSX-1 [101]. Signaling through TCCR or WSX-1 is required for the early initiation
of a Th1 response, but not necessary for the maintenance of Th1 responses [101]. The
signaling pathway initiated by IL-27 activates Jak-1 and Jak-2 molecules. However, only
STAT1 and STAT3 are critical to IL-27 bioactivities, and STAT3 rather than STAT1 is
required for IL-27-induced proliferation [102].
IL-27 is rapidly produced by human phagocytic cells and DCs after their
activation [101]. IL-27 is involved in early Th1 initiation, is able to induce proliferation
of naive but not memory T-cells, and can synergize with IL-12 in IFN-γ production [102].

C. Interleukin 35
IL-35 was discovered very recently [103]; this heterodimeric cytokine is
composed of the p35 subunit and the p40-related protein EBi3. IL-35R complex has not
been characterized yet, but it is possible that it may be composed of the receptors known
for IL-27 and IL-12, either gp130 or WSX-1 and IL-12R β2.
Within the CD4+ T-cell population, IL-35 is expressed by resting and activated T
regulatory cells (Tregs) but not activated T-cells. Loss of IL-35 expression results in
reduced immune suppression by Tregs. IL-35 appears to function as an anti-inflammatory
molecule by inhibiting T-cell proliferation. It is suggested that IL-35 can suppress Th17
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development in vivo [104]; however, further studies are required to fully understand the
exact mechanism behind these functions.

1.3.4 IL-12 Biological Activities
IL-12 is produced mainly by DCs, MФs, monocytes, neutrophils, microglia cells,
and, to a lesser extent, B-cells (Figure 5); human but not murine B cells were found to
produce IL-12 following CD40 ligation [105]. Non-immune cells such as infectedkeratinocytes and osteoblasts, epithelial, and endothelial cells have also been shown to
produce some amounts of this cytokine [106, 107]. Pathogen-associated molecular
patterns such as LPS, teichoic acid, peptidoglycan, and bacterial CpG DNA, can induce
IL-12 production. The production of IL-12 is regulated by positive and negative feedback
mechanisms involving Th1 cytokines (e.g. IFN-γ), Th2 cytokines (e.g. IL-10), and type 1
IFN (Figure 5) [108, 109].
IL-12 has multiple biological functions (Table 2) and it bridges innate and adaptive
immunity. IL-12 induces differentiation of naive CD4+ T-cells to Th1 cells and activates
NK cells. Upon activation, these cells produce IFN-γ and other type-1 cytokines [110].
IL-12 also protects CD4+ Th1 cells from antigen-induced apoptotic death [111]. IL-12
was found to have synergistic effects with IL-18 in developing Th1 cells, and IL-12 and
IL-18 reciprocally upregulate each other’s receptors [81]. In addition, IL-12 plays a role
in T-cell trafficking and migration by inducing functional adhesion molecules such as Pand E-selectin ligand expression on Th1 cells but not Th2 cells; therefore, these cells are
selectively recruited to sites where Th1 immune responses are needed [112]. Studies also
reported selective expression of CCR5 and CXCR3 when naive T-cells were primed in
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the presence of IL-12 [110, 113]. Stimulation of MФ-derived IL-12 also plays a major
role in the induction of resistance in parasitic infestation [114].

Figure 5. Summary of the biology of IL-12 [90]. Reprinted by permission from
Macmillan Publishers Ltd: Nat Rev Immunol., 3, Trinchieri, G. Interleukin-12 and the
regulation of innate resistance and adaptive immunity, 133-146, Copyright (2003).

Promote naive CD4+T-cells to differentiate into Th1
Enhance the generation and activity of cytotoxic T lymphocytes
Induce IFN-γ production by (i) NK cell, T-cell, DC, and MФ, (ii)
cooperating with B7/CD28 interaction, and (iii) synergizing with
IL-18
Increase MФ antimicrobial activity
Prime DC activation to induce more IL-12 production
Induce functional adhesion molecule expression on Th1 cells and
influence T-cell trafficking

Table 2. Main immunological functions of IL-12.
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The biological activity and quantity of IL-12 can be determined using molecular
approaches. One of the first approaches for quantifying IL-12 was based on IL-12induced proliferation of phytoheagglutinin (PHA)-stimulated lymphocytes [115].
Peripheral blood mononuclear cells activated with PHA along with IL-2 proliferate in
response to IL-12. Enzyme-linked immunosorbent assay (ELISA) was also applied to
quantify specifically IL-12p40 and IL-12p70 [116]. In combination with ELISA, another
approach, based on the ability of IL-12 to induce IFN-γ secretion from activated Tlymphoblasts, was developed and has been used to measure the biological activity of IL12 [117, 118].

1.3.5 IL-12 Therapeutic Applications in Infections
IL-12 holds considerable promise as an immunotherapeutic agent because it plays
a central role in regulating innate and adaptive immune responses and synergizes with
several other cytokines for increased immunoregulatory activities. Animal and human
studies have shown improved outcomes in treating or preventing infections based on the
mechanisms of IL-12-dependent therapies.

1.3.5.1 Viral Infections
The role of IL-12 in promoting endogenous protective immune responses to viral
infections has been attracting more attention with time. Many experimental models have
been developed to test the potential effects of IL-12 and other immune mediators on
herpes simplex virus, influenza virus, human immunodeficiency virus (HIV),
lymphocytic choriomeningitis virus, mouse cytomegalovirus, and many others [119].
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A. Herpes simplex virus
In an in vivo herpes simplex virus-1 (HSV-1) mouse model, sustained expression
of IL-12 was induced by the virus. This local IL-12 production was considered to cause
an immunopathological response in the mouse eye environment due to Th1 immunity
[120]. However, exogenous IL-12 showed a protective role and increased the resistance
to infection in HSV-1-thermally injured mice, possibly resulting from the activation of
viral-specific Th1 immunity [121]. Also, IL-12 and IL-18 were shown to play an
important role in innate immunity against genital HSV-2 infection in a mouse model; the
protection was mainly mediated by IFN-γ production [122].
B. Influenza virus
CD4+ T-cells are important in controlling influenza A virus infection. CD4+ Tcells drive the induction and expansion of cytotoxic T lymphocyte (CTL) against such
viral pathogens. Earlier studies using the influenza virus system as a model showed that
DCs induced effective CTL response without increasing endogenous IL-12 levels.
Exogenous application of IL-12 was found to significantly enhance CTL activity [123].
Studies also demonstrated a combined effective role of IL-12 and DCs together in
enhancing CTL immunity to viral infection [123]. The influenza virus vaccination
effectively protects individuals against serious complications through induction of
humoral and cellular responses [124]. Interestingly, patients identified with genetic IL12/23R β1 or IFN-γR deficiencies were found to develop immune responses to childhood
vaccination [123]. Also, influenza vaccination could induce humoral immunity and IFN-γ
production in IL-12/23R β1 deficient patients [125]. These studies may imply that both
IL-12 and IFN-γ play a significant role in fighting viral infections.
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C. Human immunodeficiency virus (HIV)
HIV infection mainly induces Th2 immunity which is unable to clear the viral
infection most of the time. Glycoprotein gp120 of HIV has been shown to induce IFN-γ
dependent production of IL-12 in cultured MФs. The use of IL-12 production and Th1
activation might contribute to decreasing viral load and increasing clearance of the
infection [126]. However, phase I trials in HIV patients have shown moderate effects
accompanied by some toxic responses [127].
1.3.5.2 Bacterial Infections
As a potent inducer of Th1 immune response and an important mediator between
innate and adaptive immunity, IL-12 has potential clinical uses in treating and preventing
bacterial infections.
A. Bone infection
Osteomyelitis is a bone infection characterized by the presence of necrotic bone
tissue and increased osteoclast activity. It is commonly caused by Staphylococcus aureus
(S. aureus), which is traditionally known as an extracellular pathogen; however, it has
been shown that S. aureus can be internalized and live within a variety of host cells [128,
129]. Internalization of S. aureus into the host cells could be an important pathogenicity
factor for escaping the host immune system leading to persistence of infection [130]. It
was reported that in vitro mouse and human osteoblasts infected with S. aureus express
high levels of IL-12 [107]; IL-12 and/or IL-23 knockout mice showed an increased
susceptibility to bacterial, parasitic, and fungal infections [131]. Therefore, IL-12 may
play a critical role in the downregulation of S. aureus growth in vivo [132].
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Figure 6. Local IL-12 therapy stimulates Th cells to secrete Th1 cytokines [63].
Exogenous IL-12 application creates an environment rich in IL-12 around the infection
site. In such a local environment, newly activated Th cells, responding to the presence of
bacteria, exit the blood and are influenced to become Th1 cells and secrete more Th1
cytokines and activate macrophages and NK cells. Activated macrophages will produce
more IL-12 via a positive feedback; cell-mediated immunity can be promoted to battle
bacteria thereby leading to the prevention of infection. Reprinted from Biomaterials, 30,
Li, B.; Jiang, B.; Boyce, B.M.; Lindsey, B.A. Multilayer polypeptide nanoscale coatings
incorporating IL-12 for the prevention of biomedical device-associated infections, 25522558, Copyright (2009), with permission from Elsevier.

More recently, studies have shown that IL-12 may play a significant role in
preventing osteomyelitis. A decrease in IL-12 production was observed upon pathogenmediated ligation of MФ Fcγ or complement receptors [133, 134]. This finding may
indicate that there are cases in which regulation of IL-12 production can be affected by
24

pathogens. Perhaps down-regulation of IL-12 has the potential of providing pathogens
with a means of suppressing cell-mediated immunity which would make pathogen
clearance takes longer and increase the risk of bacterial infections. Meanwhile, IL-12
production was shown to decrease following trauma or major burn resulting in decreased
or delayed cell-mediated immune response and decreased resistance to infection [135138]. Exogenous application of IL-12, combined with nanotechnology drug delivery
systems, may have restored the decreased IL-12 level and recovered the host’s cellmediated immune response; the combination has been found to be effective in preventing
open fracture-associated osteomyelitis [139, 140]. The mechanism of protection is related
to the enhancement of Th1 reactivity and activation of MФs at an early stage following
surgery (Figure 6) [139]. The activation of MФs may lead to enhanced antigen
presentation, phagocytosis, Fc receptor expression, and nitric oxide and superoxide
production [141]. As a result, these changes may substantially increase the ability of
MФs to kill a wide variety of intracellular and extracellular bacteria and enhance the
development of long-term immunity to those pathogens [141].

B. Tuberculosis
Tuberculosis (TB) is a common and often deadly infectious disease caused by
mycobacteria

including

Mycobacterium

tuberculosis,

Mycobacterium

bovis,

Mycobacterium africanum, Mycobacterium canetti, and others. The chronic nature of
Mycobacterium tuberculosis (Mtb) infection has led researchers to investigate the host’s
immunity to respond to and control this disease. Previous reports involving TB infection
models showed that the development of Th1 cells in response to IL-12 production and
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subsequent induction of IFN-γ are key players in immunity to TB [142]. Exogenous IL12 application was found to result in lower bacterial load and increased incidence of
survival [143]. DC and Th1 activation and migration to the infected lungs were shown to
control bacterial growth via IFN-γ–induced activation of phagocytes [144]. This immune
response, however, may not be solely mediated by IL-12, as the other IL-12 family
members (IL-23, IL-27, and IL-35) may also participate as well [87].
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CHAPTER 2
Staphylococcus aureus Internalization and Associated Biological
Responses of Osteoblasts and Macrophages
Abstract
The aims of this study were to compare Staphylococcus aureus (S. aureus)
internalization in a phagocytic cell (i.e. macrophage) to a non-phagocytic cell (i.e.
osteoblast), and to investigate the cells’ responses upon infection. We found that S.
aureus could internalize within macrophages and osteoblasts, and upon infection, a
significantly higher number of live intracellular S. aureus was observed in macrophages
compared to osteoblasts. The viability of macrophages and osteoblasts both decreased
with increasing infection time, and macrophages had significantly lower viability during
2 h infection and significantly higher viability during 8 h infection compared to
osteoblasts. Moreover, intracellular S. aureus was found to survive within macrophages
and osteoblasts for approximately 5 and 7 days, respectively. The percentage of S. aureus
survival within macrophages and osteoblasts decreased with increasing post-infection
time, and the percentage of S. aureus survival within macrophages was significantly
lower compared to that within osteoblasts. More importantly, compared to non-infected
controls, S. aureus infection resulted in (i) significantly increased hydrogen peroxide
production in macrophages and osteoblasts, (ii) significantly increased superoxide anion
production in macrophages but not in osteoblasts, (iii) relatively lower alkaline
phosphatase activity in infected osteoblasts, and (iv) higher phagocytosis activity in
infected macrophages.
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1. Introduction
Staphylococcus aureus (S. aureus) is one of the primary causes of bone infections
[1-3]. These infections are often chronic, difficult to eradicate, and cause high morbidity
rates [4]. S. aureus can gain access deep into bone and soft tissue as a result of severe
trauma or foreign body implants [5]. Although S. aureus has been traditionally
considered as an extracellular pathogen, it has been reported by several groups that this
bacterium can invade and survive within a variety of cells such as neutrophils,
macrophages, T-lymphocytes, epithelial cells, endothelial cells, fibroblasts, and
osteoblasts [6-15]. One hypothesis, not yet proven, about chronic and recurrent infections
is that bacteria internalize into the host cells and such intracellular bacteria may
potentially lead to their evasion of the host’s immune responses and protection from most
conventional antibiotics [16].
The main role of osteoblasts is to synthesize bone components and induce bone
matrix mineralization [17]. Osteoblasts are not traditionally considered as part of the
immune system. However, osteoblasts were recently found to be able to induce
inflammatory cytokines and chemokines upon S. aureus internalization [18,19]. This
finding may suggest an important role for osteoblasts in triggering immune responses
after S. aureus infection. S. aureus can be internalized into osteoblasts and its
internalization is believed to be mediated by binding of fibronectins on osteoblast
surfaces, which is connected to the integrin dimer α5β1 molecule and fibronectin-binding
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proteins on S. aureus surfaces [6]. Protein-ligand interaction leads to S. aureus adhesion
and invasion by a “zipper-like” mechanism [15]. Eventually, internalized bacteria escape
into the cytoplasm and may lead to host cell death by apoptosis [20]. In addition, live
osteoblasts are necessary for S. aureus internalization as formalin-fixed osteoblasts could
not internalize S. aureus [10,21].
The major role of phagocytes, such as macrophages, neutrophils, and dendritic
cells is to engulf and eliminate a wide variety of invading pathogens. As a result, high
influxes of such phagocytes are expected at the infection site upon pathogen invasion. For
instance, a high influx of neutrophils was detected at the infection site of S. aureus bone
infection [22]. Unfortunately, some pathogens can survive within these phagocytes after
being phagocytized which may lead to chronic diseases [23,24]. It was reported that S.
aureus can survive within neutrophils and its survival may have contributed to infection
persistence as well as dissemination in vivo [7]. Neutrophils are short-lived and are
unlikely to carry intracellular pathogens for long [25]. Macrophages, however, are long
lived and may possibly allow surviving pathogens to invade the circulatory system from
localized infection sites [26] and thereby may be more likely contribute to chronic and
recurrent infections.
The aims of this study were to compare S. aureus internalization in a phagocytic
cell (i.e. macrophage) and a non-phagocytic cell (i.e. osteoblast), and to investigate
macrophage and osteoblast responses upon S. aureus infection. We hypothesized that S.
aureus can internalize into macrophages and osteoblasts and survive for at least days, and
its internalization may lead to changes in macrophage and osteoblast activities.
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2. Materials and Methods
2.2.1. Reagents
Tryptic soy agar (TSA, w/5% sheep blood) plates, tryptic soy broth (TSB),
phosphate buffered saline (PBS), fetal bovine serum (FBS), 0.25% trypsin/2.21 mM
ethylenediaminetetraacetic acid (EDTA) solution, 45% glucose solution, 7.5% sodium
bicarbonate, sodium pyruvate, and HEPES buffer were all obtained from Fisher Scientific
(Pittsburgh, PA). Dulbecco's Modified Eagle Media: Nutrient Mixture F-12
(DMEM/F12) and RPMI-1640 media were purchased from LONZA (Walkersville, MD).
DiI fluorescent dye, Syto-9, propidium iodide (PI), and 100 U/mL penicillin/100 mg/mL
streptomycin solution were from Invitrogen (Carlsbad, CA). Gentamicin, Triton X-100,
cytochalasin D, dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), lysostaphin,
fluorescein isothiocyanate (FITC), paraformaldehyde, and glutaraldehyde were obtained
from Sigma (St. Louis, MO). Primary antibody Ab20920 and goat polyclonal to rabbit
IgG secondary antibody-Cy5 ab6564 were obtained from Abcam (Cambridge, MA).
Dichlorofluorescin diacetate (H2DCF-DA) and dihydroethidum (DHE) were from Life
Technologies (Grand Island, NY).
2.2.2. Bacteria
S. aureus (ATCC 25923) was obtained from the American Type Culture
Collection (ATCC, Manassas, VA). A fresh inoculum was prepared by suspending 5
colonies of S. aureus, grown on a blood agar plate, in 5 mL TSB and incubated at 37oC
for 18 h. After incubation, the S. aureus inoculum was centrifuged at 3750 rpm for 15
min at 4oC and washed once with 10 mL PBS to obtain an optical density of 0.80 which
yields (6-8)×108 colony forming units/mL or CFU/mL. The bacteria pellet was then re40

suspended in either DMEM/F12 for the infection of osteoblasts or in RPMI-1640 medium
for the infection of macrophages; both cell culture media were free from
streptomycin/penicillin and FBS.
2.3. Infection of osteoblasts with S. aureus
Rat osteoblasts (UMR-106) were obtained from ATCC and grown in fullsupplemented

DMEM/F12

medium

containing

10%

FBS

and

1%

of

penicillin/streptomycin solution. In 12-well plates (Fisher Scientific), 3×105 cells/mL
were seeded and cultured in full-supplemented DMEM/F12 medium for at least 24 h at
37oC in a 5% CO2 incubator until they reached ~ 80% confluence. Osteoblasts were
infected and the effects of multiplicity of infection (MOI), which represents S. aureus to
osteoblast ratio, and infection time on osteoblast infection were investigated: (1) To
examine the effect of MOI on osteoblast infection, the osteoblast monolayer was washed
3 times with PBS and then fresh DMEM/F12 media was added (free from
streptomycin/penicillin and FBS). Immediately, S. aureus was added at MOIs of 100:1,
500:1, and 1000:1 and incubated for 2 h. (2) To examine the effect of infection time on
osteoblast infection, the osteoblast monolayer was washed 3 times with PBS and then
fresh DMEM/F12 media (free from streptomycin/penicillin and FBS) was added. S.
aureus was added at an MOI of 500:1 and incubated for different times, i.e. infection
times, of 0.5, 2, 4, 6, and 8 h. After each time point, the osteoblast monolayer was
washed 3 times with PBS and treated with 100 μg/mL gentamicin (an antibiotic known
not to penetrate mammalian cell membranes within a few hours [27,28]) for 2 h at 37oC
in a 5% CO2 incubator. Osteoblasts were then washed 3 times with PBS and immediately
lysed with 0.1% Triton X-100 in PBS for 10 min at 37oC; the cell lysates were diluted in
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PBS and plated on blood agar plates overnight. To determine viability, osteoblasts were
detached by incubating them at 37oC for 3 min in a 0.25% trypsin/2.21 mM EDTA
solution; trypsinization was stopped by adding DMEM/F12 medium supplemented with
10% FBS. Viable osteoblasts were counted using a hemocytometer (Bright-Line Hausser
Scientific, Horsham, PA) following the trypan-blue exclusion assay which depends on
cellular membrane integrity; dead cells allow the stain to penetrate while live cells do not.
2.4. Infection of macrophages with S. aureus
Rat alveolar macrophage cell-line (NR 8383) was obtained from ATCC and
grown in full-supplemented RPMI-1640 medium containing 10% FBS, 1%
streptomycin/penicillin, 45% glucose solution, 7.5% sodium bicarbonate, and sodium
pyruvate. The infection of macrophages with S. aureus was studied at different MOIs and
infection times. The protocols for infecting macrophages were similar to those of
infecting osteoblasts as described previously. In brief, 3×105 cells/mL were seeded in 12well plates and cultured in full-supplemented RPMI-1640 medium for at least 24 h to
achieve adherence at 37oC in a 5% CO2 incubator. Cultured macrophages were washed 3
times with PBS and then infected with S. aureus at different MOIs (100:1, 500:1, and
1000:1) or infection times (0.5-8 h). Infected macrophages were washed, treated with
gentamicin, washed again, and then lysed to determine the number of live intracellular S.
aureus. To determine the viability of macrophages, adherent macrophages were scraped
using a cell scraper (Fisher Scientific) and combined with floating macrophages from the
same sample for trypan-blue exclusion assay and hemocytometry.

42

The viability of osteoblasts and macrophages after infection with S. aureus was
calculated relevant to their control (non-infected) cells according to the following
equation:

Note that the total cell numbers in the infected and control samples were the same
at the beginning of the infection (i.e. infection time = 0 h) but were different at later
infection time periods (i.e. 0.5-8 h).
2.5. Inhibition of S. aureus internalization in osteoblasts
Cytochalasin D was re-constituted in 1% DMSO; 3×105 cells/mL were seeded in
12-well plates and cultured in full-supplemented DMEM/F12 medium to reach ~ 80%
confluence. The osteoblast monolayer was washed 3 times with PBS and then fresh
DMEM/F12 media was added (free from streptomycin/penicillin and FBS) together with
cytochalasin D (0.5, 1, 5, 10, and 20 µg/mL). After culturing for 30 min, S. aureus was
added at an MOI of 500:1 and further incubated for 2 h. Following treatment with
gentamicin, infected osteoblasts were lysed and plated to determine the number of live
intracellular bacteria.
2.6. Survival of S. aureus within osteoblasts or macrophages
Osteoblasts or macrophages were infected with S. aureus at an MOI of 500:1 for
2 h, treated with gentamicin, washed, and cultured for up to a week in DMEM/F12 (for
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osteoblasts) or RPMI-1640 (for macrophages) supplemented with 5% FBS and 5 μg/mL
lysostaphin; lysostaphin does not penetrate mammalian cell membranes for long time
periods, e.g. weeks [29-31]. The cell culture media was changed every 3 days. At postinfection days 0, 1, 3, 5, 6, 7, and/or 8 and 9, independent samples of infected cells were
washed with PBS, lysed with 0.1% Triton X-100, and plated on blood agar plates to
determine the number of live intracellular S. aureus. Percentage of live intracellular CFU
at different times following infection was calculated based on the live intracellular CFU
immediately after infection (i.e. post-infection day 0).
2.7. Confocal microscopy
A dual staining approach [32,33] was adopted to visualize intracellular S. aureus.
Osteoblasts or macrophages were cultured on rounded cover-slips for at least 24 h in fullsupplemented DMEM/F12 or RPMI-1640, respectively. Fresh S. aureus was cultured for
18 h at 37oC in a 5% CO2 incubator. After washing the bacteria once with PBS, the pellet
was stained with 100 μg/mL FITC in PBS for 30 min at room temperature prior to
infection. Excess FITC was removed by washing with PBS and centrifugation at 3750
rpm for 15 min at 4oC. After infecting with the stained S. aureus for 2 h at an MOI of
500:1, osteoblasts were trypsinized using a 0.25% trypsin/2.21 mM EDTA solution for
30 seconds at room temperature to remove adherent extracellular S. aureus; no
trypsinization was used in the macrophage samples. Osteoblasts or macrophages were
then fixed with 4% paraformaldehyde in distilled water for 30 min at room temperature.
Fixed cells were washed 3 times with PBS and blocked with 5% BSA for 1 h at room
temperature. To further label the extracellular S. aureus, the fixed cells were incubated
overnight at 4oC with a primary antibody Ab20920S in 5% BSA, washed 3 times with
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PBS (to remove excess free primary antibody), and then incubated in the dark with a
secondary antibody-conjugated Cy5 fluorescent dye in 2.5% BSA for 45 min at room
temperature. After washing the excess secondary antibody with PBS, the cover-slips were
flipped onto microscopic glass slides and used for image observation; macrophage
samples were mounted in the presence of 4',6-diamidino-2-phenylindole (DAPI)
fluorescent dye to visualize the nuclei of macrophages. Slides were visualized using a
159 Plan-Apochromat 63x/1.40 oil objective on an LSM 510 confocal microscope (Zeiss,
Jena, Germany).
To confirm the presence of live intracellular S. aureus and the efficacy of
gentamicin killing of extracellular S. aureus, osteoblasts were seeded on a rounded coverslip overnight. The monolayer was then stained with DiI fluorescent dye for 20 min at
37oC in the dark. The monolayer was washed once with PBS and infected with Syto-9
labeled S. aureus as aforementioned. After gentamicin treatment, infected osteoblasts
were washed 3 times with HEPES buffer and PI stain was added for 15 min at room
temperature in the dark. Immediately after washing off the excess PI, the slides were
examined under the LSM 510 confocal microscope and images of Z-stack sections were
taken to confirm the live intracellular S. aureus. Z-stack sections were generated and the
X-Y planes showed that all live (green) S. aureus was inside the osteoblasts.
2.8. Transmission electron microscopy (TEM)
Osteoblasts were infected with S. aureus at an MOI of 500:1 for 2 h, washed once
with PBS, and detached using trypsin-EDTA. Osteoblasts were then collected by
centrifugation at 1200 rpm at 4oC for 7 min, and the pellet was washed twice with PBS
then fixed with 2% paraformaldehyde and 4% glutaraldehyde mixed with 0.075 M PBS
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for 30 min at room temperature. The fixed cell mass was collected in 1.5 mL Eppendorf
tubes. The cell pellet was washed 3 times with PBS, post-fixed in 1% osmium tetroxide
for 2 h at room temperature, washed 3 times with PBS, treated with aqueous 1% tannic
acid for 1 h at room temperature, and then dehydrated in a gradient ethanol series. The
cells were embedded in pure LR white resin solution and polymerized at 60°C for 2448 h. Thin (0.1 μm) sections were cut and placed on nickel grids, stained with 2% uranyl
acetate and lead citrate, and viewed using TEM (JEOL, Peabody, MA).
2.9. Reactive oxygen species production
Osteoblasts and macrophages were infected with S. aureus at an MOI of 500:1. At
pre-determined time points (0.5, 1, and 2 h), samples of infected osteoblasts or
macrophages were taken, washed once with PBS, and then incubated with H2DCF-DA
or DHE at 37 C for 1 h in the dark; separate samples were used for the staining of
H2DCF-DA and DHE. Non-infected osteoblasts and macrophages were used as controls
and were treated the same as the infected cells except no S. aureus was added. Viable
cells of infected and control samples at the pre-determined time points were obtained
using hemocytometry and were used to analyze the final fluorescent data. The
fluorescence intensity was measured using a fluorescent microplate reader (BioTek
Instrument, Inc., Winooski, VT) at 492 nm/520 nm for 2',7'-dichlorofluorescein (DCF),
converted intracellularly from H2DCF-DA, and 492 nm/620 nm for DHE. H2DCF-DA
and DHE are commonly used to stain intracellular hydrogen peroxide (H2O2) and
superoxide anion (O.2-), respectively [34]. The acetate groups of H2DCF-DA are cleaved
by intracellular esterases and oxidation and convert to highly fluorescent DCF.
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2.10. Osteoblast alkaline phosphatase (ALP) activity
Osteoblasts were cultured in 12-well plates at a density of 5×104 cells/mL,
infected at an MOI of 500:1 for 2 h following the aforementioned infection protocol.
Non-infected (control) and infected osteoblasts were cultured in DMEM/F12
supplemented with 5% FBS and 5 μg/mL lysostaphin solution for a week; media was
changed every 3 days. On post-infection days 1, 4, and 7, osteoblast monolayers were
washed with PBS once and the ALP activity was determined using an ALP assay kit
(Abcam) and expressed as Unit/mL.
2.11. Macrophage phagocytosis assay
Macrophage phagocytosis (ingestion) activity was tested by measuring the uptake
of FITC-labeled S. aureus by non-infected (control) macrophages and macrophages
infected with S. aureus (unlabeled) at an MOI of 500:1 for 2 h. After incubating 5×105
cells/mL non-infected (control) and infected macrophages separately with FITC-labeled S.
aureus at 10:1 MOI for 2 h, macrophages (infected and non-infected) were treated with
100 μg/mL gentamicin for 2 h at 37 C in a 5% CO2 incubator. Macrophages were then
scraped and collected for flow cytometry analysis using BD-FACS Calibur (BD, Franklin
Lakes, NJ); 10,000 events were collected. Data were acquired in logarithmic mode for the
forward scatter (FSC), side scatter (SSC), and green fluorescence channel FL-1H (i.e.
FITC). Control macrophages were subjected to the same experimental protocols as the
infected cells but without infection with S. aureus. The percentage of macrophages with
FITC fluorescent intensity corresponds to the ingestion activity of macrophages.
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2.12. Statistical analysis
Statistical analyses were performed using JMP Statistical Visualization Software
(SAS Institute, Cary, NC). Experiments were repeated at least twice on separate days to
verify reproducibility. All data were expressed as mean ± SD and analyzed using oneway analysis of variance (ANOVA). Statistical significance was set at p<0.05.
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3. Results
3.1. Characterization of S. aureus infection of osteoblasts and macrophages
After incubating with S. aureus for 2 h at an MOI of 100:1 to 1000:1, osteoblasts
and macrophages were both found to be infected. However, significantly higher (~ 2
orders) numbers of intracellular S. aureus were found within macrophages compared to
osteoblasts (Figure 2A); the intracellular CFUs for infected macrophages and osteoblasts
were approximately 3.5×106 and 3.1×104 CFU/(105 cells), respectively. No significant
differences were observed in the same cell type at the various MOIs studied (i.e. 100:1,
500:1, and 1000:1). By contrast, significantly lower viability was observed in
macrophages compared to osteoblasts at 2 h infection; the viability of macrophages and
osteoblasts were 62-78% and 90-95%, respectively (Figure 2B). No significant
differences in viability for the same cell type at the MOIs investigated (i.e. 100:1, 500:1,
and 1000:1) were noticed following the 2 h infection.

At an MOI of 500:1, the number of intracellular S. aureus for both macrophages
and osteoblasts increased with increasing infection time and reached a plateau at 2 h, at
which point the intracellular CFUs for macrophages and osteoblasts were 5.0×106 and
3.9×104 CFU/(105 cells), respectively (Figure 2C). At the infection times of 2-8 h, the
intracellular CFUs for macrophages were significantly (about 2 orders) higher than those
of osteoblasts. At an MOI of 500:1, the viability of macrophages and osteoblasts
decreased approximately linearly with increasing infection time. The viability of
macrophages at infection times of 2, 4, 6, and 8 h was significantly lower than that of
both macrophage control and at infection time of 0.5 h. The viability of osteoblasts at
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Figure 2. S. aureus infection of osteoblasts and macrophages. (A) Live intracellular S.
aureus and (B) viability of osteoblasts and macrophages at different MOIs (100:1, 500:1,
and 1000:1) for 2 h. *p<0.05 and **p<0.001 compared to osteoblasts at the same MOI.
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infection times of 4, 6, and 8 h was significantly lower than that of both osteoblast control
and at infection time of 0.5 h (Figure 2D). In addition, the viability of macrophages was
significantly lower at 2 h infection but significantly higher at 8 h infection compared to
osteoblasts at corresponding infection time periods (Figure 2D).
The S. aureus infection of osteoblasts was also found to be significantly inhibited
by the addition of cytochalasin D. The intracellular CFUs of S. aureus decreased
significantly with increasing cytochalasin D at the dose range studied (0.5-20 μg/mL),
reaching 50% inhibition at 20 μg/mL (Figure 2E). Relatively higher cytochalasin D doses
of 10 and 20 μg/mL also led to significantly lower intracellular CFUs of S. aureus

S. aureus CFU/10^5 cell

compared to the doses of 0.5, 1, and 5 μg/mL (Figure 2E).
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Figure 2 (C). S. aureus infection of osteoblasts and macrophages. Live intracellular S.
aureus and at an MOI of 500:1 for various infection times. **p<0.001 compared to
osteoblasts at the same infection time.
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S. aureus was found to be able to survive within macrophages and osteoblasts for
approximately a week; live intracellular S. aureus was found in macrophages and
osteoblasts for 5 and 7 days, respectively (Figure 3). The percentage of live intracellular S.
aureus for both macrophages and osteoblasts decreased continuously with increasing
culturing time after infection, and significantly reduced survival of S. aureus was found
in macrophages compared to osteoblasts at the same post-infection time period (Figure 3).
In addition, no differences in osteoblast proliferation were observed between infected and

S. aureus survival (%)

non-infected osteoblasts within one week post-infection (data not shown).
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Figure 3. Survival of intracellular S. aureus within osteoblasts and macrophages after
infection at an MOI of 500:1 for 2 h. **p<0.001 compared to osteoblasts at the same postinfection time.
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Confocal microscopy and TEM images confirmed that S. aureus was internalized
and could survive within macrophages and osteoblasts (Figure 4). Meanwhile,
substantially more (likely two orders) S. aureus was internalized (not necessarily alive)
by macrophages compared to osteoblasts (Figure 4A and B). Confocal microscopy
imaging also found that all live S. aureus was inside the osteoblasts and there were no
live S. aureus on the surface of the osteoblasts after gentamicin treatment (Figure 4C).
The internalization of S. aureus within osteoblasts was found to be non-uniform as some
osteoblasts had multiple S. aureus bacteria while others had none (Figure 4D).

Figure 4 (A)
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Figure 4 (B)
Figure 4. Visualization of intracellular S. aureus within (A) macrophages and (B)
osteoblasts. Osteoblasts and macrophages were infected with S. aureus at an MOI of
500:1 for 2 h. (A and B) S. aureus was stained with FITC before infection. Infected
osteoblasts and macrophages were fixed, blocked, stained first with primary antibody to S.
aureus surface protein A, and then secondary antibody conjugated to Cy-5. The nuclei of
the macrophages were additionally stained with DAPI. Visualized at (I) 488 nm, (II) 633
nm, and (III) 405 nm. (IV) Merged images of (I), (II), and (III). As a result, intracellular S.
aureus is shown in green (FITC) and extracellular S. aureus is co-localized with both red
(Cy-5) and green (FITC).

55

Figure 4. Visualization of intracellular S. aureus within osteoblasts. (C) Z-stack sections
were used to confirm that all live S. aureus was inside osteoblasts as determined by the
X-Y planes. Live S. aureus are green (Syto 9) and dead S. aureus are red (PI).
Osteoblasts were infected with Syto 9-labeled S. aureus, then extracellular bacteria were
killed with gentamicin and washed. Osteoblasts were detached from the wells and stained
with PI. Approximately 20 cells (randomly selected) were examined.

3.2. Biological responses of osteoblasts and macrophages upon S. aureus infection
Significantly higher H2O2 levels were observed at 0.5 and 1 h in infected
osteoblasts compared to non-infected osteoblasts, i.e. control (Figure 5A). Significantly
higher H2O2 levels were also observed following a 1 h infection in macrophages
compared to non-infected control (Figure 5A). No significant changes in O.2- production
in osteoblasts were observed at the infection time periods studied (i.e. 0.5, 1, and 2 h),
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while significantly higher O.2- levels were found in macrophages at 0.5 and 1 h infection
(Figure 5B).

Figure 4 (D). Visualization of intracellular S. aureus within osteoblasts. Confirmation of
intracellular S. aureus within osteoblasts using TEM.
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Figure 5. Cellular and molecular responses of osteoblasts and macrophages infected
with S. aureus at an MOI of 500:1 for 2 h. (A) DCF fluorescence intensity as an indicator
of H2O2 production by non-infected controls and S. aureus-infected osteoblasts and
macrophages. (B) DHE fluorescence intensity as an indicator of O.2- production by noninfected controls and S. aureus-infected osteoblasts and macrophages. *p<0.01, **p<0.001,
and ***p<0.0001 compared to control.
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No significant changes in ALP enzyme activity were found between infected and
non-infected osteoblasts at post-infection days 1, 4, and 7, although the ALP activity was
lower for the infected cells at days 4 and 7 (Figure 5C). The macrophage phagocytosis
activity studies showed that the ability to ingest bacteria was much higher for infected
macrophages (83%) compared to non-infected ones (44%) (Figure 5D).
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Figure 5 (C). Cellular and molecular responses of osteoblasts and macrophages infected
with S. aureus at an MOI of 500:1 for 2 h. Osteoblast ALP activity measured at postinfection days 1, 4, and 7.
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Figure 5 (D). Cellular and molecular responses of osteoblasts and macrophages infected
with S. aureus at an MOI of 500:1 for 2 h. Macrophage phagocytosis activity (ingestion).
Light gray area: control macrophages without incubation with S. aureus; dark gray area:
non-infected macrophages; black area: infected macrophages. *p<0.01, **p<0.001, and
***
p<0.0001 compared to control.
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4. Discussion
S. aureus has been traditionally considered as an extracellular pathogen; however,
it has been shown to invade and survive within both non-phagocytic and phagocytic cells.
By nature, the internalization and survival of S. aureus within non-phagocytic and
phagocytic cells would be expected to be different, and may play significantly different
roles in related diseases. To our knowledge, there are no reports comparing S. aureus
infection of a non-phagocytic cell with a phagocytic cell. Therefore, the main goal of the
present study was to compare the internalization behavior and related biological
responses of S. aureus in a non-phagocytic cell (i.e. osteoblast) and a phagocytic cell (i.e.
macrophage). Our findings may contribute to the understanding of the pathogenesis of
many chronic and recurrent infections.
First, we showed that S. aureus can be internalized by both osteoblasts and
macrophages. The infection of osteoblasts and macrophages was observed as early as 0.5
h at an MOI of 500:1; the corresponding live intracellular CFUs of S. aureus for
osteoblasts and macrophages at 0.5 h were 1.4×103 and 7.2×104 CFU/(105 cells),
respectively (Figure 2C). With increasing infection time, the intracellular CFUs of both
osteoblasts and macrophages increased significantly from 0.5 h to 2 h followed by a
plateau from 2 h to 8 h (Figure 2C). Since macrophages are supposed to engulf and
eliminate pathogens on contact, it was not surprising to find that, at the same infection
conditions (i.e. MOI of 500:1 for 2 h), significantly more (approximately two orders) S.
aureus (live and dead) was phagocytized by macrophages compared to those internalized
by osteoblasts (Figure 4A and B). Similarly, significantly more live intracellular S.
aureus was seen in macrophages compared to osteoblasts during infection times 2-8 h
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(Figure 2A and C). Macrophages had significantly lower viability at a shorter infection
time period (i.e. 2 h) and significantly higher survival at a longer infection time (i.e. 8 h)
compared to infected osteoblasts (Figure 2D). In addition, it is possible that the
accumulation of toxins produced by S. aureus [35,36] and the significantly higher levels
of H2O2 in infected osteoblasts and macrophages and O.2- in infected macrophages
(Figure 5A and B) affected the viability of macrophages and osteoblasts; both decreased
(almost linearly) with increasing infection time (Figure 2D). It also seems that actin
cytoskeleton formation plays a major role in S. aureus internalization into osteoblasts
since cytochalasin D, an inhibitor that disrupts actin filament polymerization, could lead
to up to 50% inhibition of S. aureus internalization (Figure 2E). This finding was
consistent with other studies [21,37] where actin filament was determined to play a
dominant role in S. aureus internalization.
Note that our data (Figure 4C) confirmed that gentamicin treatment was effective
in eliminating extracellular S. aureus and the post-infection CFU was indeed from live
intracellular S. aureus. Gentamicin treatment is commonly used to eliminate extracellular
bacteria [19,37], but such a procedure lacks direct confirmation of live intracellular
bacteria. In this study, the dual staining approach combined with confocal microscopy
presented direct evidence that no live extracellular S. aureus was observed after the
gentamicin treatment (Figure 4C).
Next, we found that S. aureus could survive intracellularly for up to 5 and 7 days,
respectively, within macrophages and osteoblasts (Figure 3). As a phagocytic cell,
macrophages were obviously more effective than osteoblasts at not only phagocytizing
but also destroying the intracellular bacteria. This observation was supported by the
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findings that S. aureus infection not only significantly increased the H2O2 levels in
macrophages at 1 h infection but also significantly increased the O.2- levels in
macrophages at infection times of 0.5 and 1 h (Figure 5A and B). In contrast, S. aureus
infection induced significantly higher levels of H2O2 in osteoblasts at 0.5 and 1 h
infection but did not induce significant changes in O.2- levels in osteoblasts (Figure 5A
and B). As a result, significantly higher intracellular CFUs were found in macrophages
immediately after infection (Figure 2C) while significantly less intracellular S. aureus
survived in the following days after infection (Figure 3). Complete elimination of the
intracellular bacteria by macrophages was found at an earlier time period (day 5 vs. day
7) compared to osteoblasts (Figure 3). Survival of S. aureus within host cells was also
reported in other cell types. For instance, S. aureus was found to survive within human
lung epithelial cells for up to 2 weeks [38], persisting in macrophage vacuoles for 3-4
days before escaping into the cytoplasm and causing macrophage lysis [6], and remaining
viable for up to 5 days within HT-29 and Caco-2 enterocytes [39]. It was proposed that,
once inside osteoblasts, macrophages, or other cells, S. aureus may undergo phenotypic
switching to small colony variants (SCVs), which are associated with increased
anchoring of fibronectin-binding proteins and clumping factors on the bacterial surface
[40,41]. These proteins may function as substrates for bacterial enzymes needed to evade
phagocytic oxidative killing [6,42] thereby contributing to the intracellular survival of S.
aureus. Moreover, S. aureus produces catalase, which catalyzes the decomposition of
H2O2, thereby protecting itself inside host cells such as macrophages [43]. It was believed
that the phenotypic switching of S. aureus may make the bacteria more resistant to
antibiotics [16,44]. The survival of S. aureus within cells like macrophages and
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osteoblasts and the possible phenotypic switching of S. aureus may explain why
antibiotics have so often failed to cure Staphylococcal infections [2,16,41]. Future studies
may focus on investigation of the possible changes that occur to S. aureus after
internalization into osteoblasts and macrophages.
Lastly, we found that S. aureus infection resulted in significantly increased levels
of H2O2 in infected osteoblasts at infection times of 0.5 and 1 h and in infected
macrophages at infection time of 1 h (Figure 5A). The O.2- levels in infected
macrophages significantly increased at infection times of 0.5 and 1 h (Figure 5B). The
increase in reactive oxygen species indicates that S. aureus internalization induced
significant stress in osteoblasts and macrophages which would produce such chemicals to
eliminate the invading pathogens. S. aureus infection also resulted in much higher
phagocytosis activity of macrophages (Figure 5D) and relatively lower (although not
significant) ALP activity of osteoblasts at days 4 and 7 after infection (Figure 5C). This
effect could be associated with the significant increase in H2O2 and O.2- levels. It is
noteworthy that, besides the significant changes in reactive oxygen species, S. aureus
internalization in osteoblasts also led to significantly higher production of IL-6 and IL-12
[19,45], macrophage chemoattractant protein 1, IL-8, IP-10, RANTES [19,45], and
RANK-L and prostaglandin E2 (two important molecules that can promote
osteoclasteogenesis and bone resorption) [46].

64

5. Conclusions
In this study, we intended to compare two infection models of osteoblast-S.
aureus and macrophage-S. aureus. We found that S. aureus could internalize in
macrophages and osteoblasts, that the internalization increased substantially with
increasing infection time from 0.5 h to 2 h, and that the internalization process may have
been primarily mediated by osteoblast actin cytoskeleton formation. Internalized S.
aureus could survive within macrophages and osteoblasts for up to 5 and 7 days,
respectively. Our confocal and transmission electron microscopy observations clearly
confirmed the presence of live S. aureus within osteoblasts and macrophages and that
gentamicin treatment was effective in killing extracellular S. aureus; no live extracellular
S. aureus was detected after gentamicin treatment. Transmission electron microscopy
also demonstrated that the internalization in osteoblasts was not uniform; some
osteoblasts had several bacteria while others had none. Confocal microscopy observation
showed that significantly more S. aureus was internalized in macrophages compared to
osteoblasts. Similarly, a significantly higher (two orders) level of live intracellular S.
aureus was detected in macrophages compared to osteoblasts at 2 h infection among
different MOIs (i.e. 100:1, 500:1, and 1000:1) and at different infection times (2-8 h) at
an MOI of 500:1. However, the percentage of S. aureus survival after infection was
significantly lower in macrophages compared to osteoblasts at post-infection days 1-6.
The viability of macrophages and osteoblasts both decreased with increasing infection
time between 0-8 h and macrophages had relatively lower viability at shorter infection
time periods (i.e. 0.5-4 h; significant at 2 h) and higher viability at longer infection time
periods (i.e. 6-8 h; significant at 8 h) compared to osteoblasts.
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S. aureus infection also led to noticeable changes in macrophages and osteoblasts.
Significantly increased H2O2 production was observed in osteoblast-S. aureus infection at
0.5 and 1 h and in macrophage-S. aureus infection at 1 h. At 0.5 and 1 h infection,
significantly increased superoxide anion production was found in macrophages. Infected
osteoblasts had relatively lower ALP activity at post-infection days 4 and 7 and infected
macrophages had higher phagocytosis activity compared to non-infected cells. Since
chronic and recurrent bone infections have been frequently reported, are often associated
with S. aureus and may be related to the intracellular persistence of S. aureus within host
cells (e.g. osteoblasts, macrophages), the present study helps to better elucidate S. aureus
internalization and its effects on host cells. This study may assist in evaluating the
pathogenesis of chronic and recurrent infections and developing new therapeutic
strategies against intracellular bacteria and diseases.
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CHAPTER 3
44%

83%

Intracellular Staphylococcus aureus Causes Bone Infection: In vivo
Evidence
Abstract
Chronic and recurrent bone infections occur frequently but have not been fully
explained. Staphylococcus aureus (S. aureus) is often found in these chronic and
recurrent infections and may be responsible for such infections. One possible reason is
that S. aureus can internalize and survive within host cells and by doing so, S. aureus can
evade both host defense mechanisms and most conventional antibiotic treatments.
However, no in vivo evidence in the literature has shown that S. aureus internalized into
host cells is directly responsible for infections. In this study, we hypothesized that intracellular S. aureus could induce infections in vivo. Osteoblasts were infected with S.
aureus and, after eliminating extra-cellular S. aureus, the osteoblasts were inoculated into
an open femur fracture rat model. Bacterial cultures and radiographic observations
confirmed local bone infections in animals inoculated with intra-cellular S. aureus within
osteoblasts alone at post-operative day 21. We present the first direct in vivo evidence
that intra-cellular S. aureus could be sufficient to induce bone infection in animals; we
found that intra-cellular S. aureus inoculation of as low as 102 colony forming units could
induce severe bone infections. Our data may suggest that intra-cellular S. aureus can
“hide” in host cells during symptom-free periods and, under certain conditions, they may
escape and lead to infection recurrence. Intra-cellular S. aureus therefore could play an
important role in the pathogenesis of S. aureus infections, especially those chronic and
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recurrent infections in which disease episodes may be separated by weeks, months, or
even years.
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Introduction
Bone infection or osteomyelitis is a significant clinical problem which can lead to
prolonged hospitalization, sepsis, poor functional outcome, and even death [1-4]. Patients
with traumatic open fractures have a high risk of infection (5-33%) due to microbial
contamination and soft tissue damage [5], and such infections are often hard to eradicate,
long-lasting (i.e. chronic), and recurrent [6]. For instance, over a million Americans are
hospitalized every year for bone fractures [7]; such injuries are increasingly common
because of increased survivability of high energy trauma in civilian settings as well as in
combat activities. Treatment of bone infections, particularly chronic and recurrent
infections, frequently requires long-term hospitalization for repeated debridement and
prolonged parenteral antibiotic therapy. Bacteria including Staphylococcus aureus (S.
aureus), however, are often surprisingly successful in overcoming both host defense
mechanisms and antibiotic treatments resulting in chronic and recurrent bone infections;
indeed, a high rate of recurrence or relapse of bone infections was reported where ~17%
of infections related to traumatic extremity injuries recur or relapse [8, 9]. It is thought
that bacteria may elude host defenses and antibiotics and can “hide” themselves
intracellularly within host cells [10]. Unfortunately, evidence to support the hypothesis
that intracellular bacteria are responsible for or contribute to bone infections in animals or
humans is sparse or does not exist.
A wide range of bacterial species have been isolated related to bone infections.
The pathogen S. aureus is the most common causative agent of bone infections,
contributing to approximately 80% of all human disease cases [11]. S. aureus is a normal
flora that colonizes the skin, skin glands, and mucous membranes, specifically in the nose
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of healthy individuals. S. aureus expresses a large number of cell surface proteins (i.e.
adhesins) of the microbial surface components recognizing adhesive matrix molecules or
MSCRAMMs [12, 13] through which it can colonize the bone matrix and adhere to bone
cell surfaces. S. aureus, while generally considered an extracellular pathogen, is one such
bacterium that has the ability to invade and live within different cell types, including
phagocytic and non-phagoytic cells (reviewed in reference 14). By “hiding” inside the
host cells, S. aureus may escape from host defenses and most antibiotic treatments and
may be responsible for chronic and recurrent bone infections.
To our knowledge, there is no definitive in vivo evidence showing that S. aureus
“hiding” intracellularly is directly responsible for or contributes to infections. The
objective of this study was to determine whether intracellular S. aureus can induce bone
infections in a rat model. By pre-infecting osteoblasts in vitro with S. aureus, killing
extracellular bacteria with gentamicin, and inoculating infected osteoblasts into an open
femur fracture rat model, we examined the bone infections in rats induced by intracellular
S. aureus.
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Materials and Methods
Reagents
Dulbecco’s modified Eagle’s medium-F 12 (DMEM-F 12) and phosphate
buffered saline (PBS) were purchased from Lonza (Walkersville, MD). Tryptic soy broth
(TSB) and tryptic soy agar (TSA w/5% sheep blood) plates were from Fisher Scientific
(Pittsburgh, PA). Fetal bovine serum (FBS), 0.25% trypsin-ethylenediaminetetraacetic
acid (EDTA), and 100 U/mL penicillin/100 mg/mL streptomycin were obtained from
Invitrogen (Carlsbad, CA). Triton X-100 was from Sigma (St. Louis, MO). S. aureus
(American Type Culture Collection or ATCC 25923) and rat osteoblast cells (UMR-106)
were purchased from ATCC (Manassas, VA).
Preparation of osteoblasts with intracellular S. aureus via co-culturing osteoblast-S.
aureus
Rat osteoblast cells were seeded at a density of 5×105 osteoblasts/mL and cultured
in 6-well plates overnight to form a monolayer in DMEM-F12 supplemented with 10%
FBS and 1% penicillin/streptomycin solution. Fresh S. aureus inoculum was prepared by
suspending 5 colonies of S. aureus into 5 mL TSB, and incubated at 37oC for 18 h. The
bacterial suspension was centrifuged (3750 rpm) at 4oC for 15 min, washed once with
PBS, and its optical density was then adjusted to have S. aureus of 5×108 colony forming
units/mL (CFU/mL). Rat osteoblasts and S. aureus were then infected as follows (Fig. 1):
(i) Osteoblast monolayer was first washed twice with PBS. S. aureus was pelleted, resuspended in DMEM-F12 (without FBS and antibiotics), and then added to the osteoblast
monolayer at a multiplicity of infection (MOI) of 500:1 S. aureus to osteoblasts.
Osteoblasts and S. aureus were next infected at 37oC in 5% CO2 humidified incubator for
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2 h. (ii) The osteoblast monolayer was then washed twice with PBS to remove any nonadherent bacteria, and cell culture media supplemented with gentamicin (100 μg/mL) was
added and kept for 2 h to kill remaining extracellular bacteria; gentamicin is an antibiotic
that is unable to penetrate mammalian cell membranes within short time periods [2, 15,
16]. Infected osteoblasts were immediately used or kept on ice before being used in the
rat animal studies. (iii) Samples of infected osteoblasts were lysed using Triton X-100.
(iv) Cell lysates were cultured on blood agar plates to determine the CFU which
represents the viable colonies of intracellular S. aureus within osteoblasts.

Figure 1. A schematic diagram describes the process of infecting osteoblasts with
intracellular S. aureus and confirming that the osteoblasts are infected. (i) Rat osteoblasts
were infected with S. aureus for 2h. (ii) Extracellular S. aureus were killed with
gentamicin and washed. (iii) Osteoblasts were lysed using a lysing buffer. (iv) Cell
lysates were cultured on blood agar plates to count live intracellular S. aureus colonies.
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Animal groups and open fracture infection procedure
Sprague-Dawley rats (400-500 g) were obtained from Hilltop Lab Animals
(Scottdale, PA). All studies were approved by the West Virginia University Institutional
Animal Care and Use Committee. Our open femur fracture rat model [17, 18] was
modified and the surgical procedure was described in brief as follows (Fig. 2): After
sedation of the animals with intraperitoneal anesthetic, the hind leg was shaved prior to
fracture. A midshaft femur fracture was produced using a custom-made device (Fig. 2A),
an incision was made to expose the fracture (Fig. 2B), and then the fracture was fixed
using an intramedullary stainless steel Kirschner wire or K-wire (Fig. 2C). Next, 100 μL
of treatment solution was gently pipetted into the fracture site without contacting the
surgical instruments (Fig. 2D). Based on the treatment solutions, rats were randomly
assigned into the following six groups (six rats per group):

Group
Group I
Group II
Group III
Group IV
Group V
Group VI

Treatment solution (100 µL)
PBS
106 osteoblasts
106 osteoblasts combined with 20 CFU of extracellular S. aureus
106 osteoblasts with *102 CFU intracellular S. aureus
106 osteoblasts (infected) with 106 CFU intracellular S. aureus
106 osteoblasts (infected) with 106 CFU intracellular S. aureus combined
with 20 CFU of extracellular S. aureus

* This was obtained by diluting the 106 CFU of intracellular S. aureus with non-infected osteoblasts.

The incision was subsequently closed (Fig. 2E) and post-operative radiographs were
taken to verify the fracture fixation. All animals were monitored for the study duration of
three weeks and euthanized on post-operative day 21.
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A
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Figure 2. The rat femur was fractured, fixed with a K-wire, and inoculated with 0.1 mL
solution of PBS, osteoblasts, mixture of osteoblasts and extracellular S. aureus (20 CFU),
infected osteoblasts with intracellular S. aureus, or mixture of infected osteoblasts and
extracellular S. aureus (20 CFU). Rats were euthanized on post-operative day 21. (A)
Creation of a femur fracture using a custom-designed setup. (B) Exposure of the fracture.
(C) Intramedullary fixation of the fracture using a K-wire. (D) Injection of 0.1 mL
solution using a pipette. (E) Closure of incision.
Microbiological and radiographic evaluations
On the day of euthanasia, bone and muscle tissues were collected in 15 mL centrifuge
tubes with 5 mL PBS and homogenized. Samples of bone and muscle homogenates were
diluted and plated on blood agar plates, and S. aureus colonies were counted after
incubating the plates, at 37oC for 24h. In addition, K-wires that were used to fix the
fractured femurs were collected at euthanasia, cut into 2cm-long pieces, rolled on blood
agar plates and cultured at 37oC for 24 h. Radiographs of fractured femurs were taken on
post-operative days 0, 7, and 21.
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Body weight and complete blood count
The body weights of animals were measured on the day of surgery and
immediately before euthanasia and the net weight gain/loss was calculated. Blood
samples were collected immediately prior to euthanasia from the heart and analyzed for
complete blood counts by Antech Diagnostics, Inc. (Southaven, MS).
Statistical analysis
Values of CFU, body weight gain/loss, and blood cell counts were expressed as
the mean ± standard deviation. Differences in body weight gain and blood cell counts
were analyzed using one-way ANOVA. P value ≤ 0.05 was considered statistically
significant. JMP (V9) software was used (SAS Institute, Inc., Cary, NC).

79

Results
Intracellular S. aureus causes high bacterial burden in bone and muscle tissues
Rats (Groups IV, V, and VI) inoculated with infected osteoblasts (102 or 106 CFU
of intracellular S. aureus) led to high CFU counts (i.e. ~106 CFU/mL) on post-operative
day 21 in the bone and muscle samples (Fig. 3A). There were no significant differences
in CFUs among the animal groups (i.e. Groups IV, V, and VI) inoculated with infected
osteoblasts on post-operative day 21, although relatively higher CFU counts were found
in the bone samples compared to the muscle samples of the same animal group. By
contrast, no bacteria were observed on post-operative day 21 in the rats (i.e. Groups I, II,
and III) inoculaed with PBS, osteoblasts, and osteoblasts combined with 20 CFU of
extracellular S. aureus (Fig. 3A). Correspondingly, heavy bacterial growth was seen in
the blood agar plates rolled with the K-wires from animals inoculated with infected
osteoblasts (102 or 106 CFU) while no bacterial colonies were found in rolling K-wires
extracted from animals inoculated with PBS, osteoblasts, and osteoblasts combined with
20 CFU of extracellular S. aureus (Fig. 3B). Gross observation before euthanasia showed
pus pockets at the fracture sites in rats inoculated with infected osteoblasts (i.e. Groups
IV, V, and VI). No S. aureus growth (data not shown) was observed on post-operative
day 21 in the blood samples collected from all the animal groups studied.
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Figure 3 (A)

Figure 3 (B)
Figure 3. (A) Bone (femur) and muscle tissue homogenates reported high S. aureus
CFUs in the animal groups inoculated with infected osteoblasts (i.e. Groups IV, V, and
VI); data were from six rats. No CFU was found in the animal groups inoculated with
PBS, osteoblasts, and a mixture of osteoblasts and extracellular S. aureus (20 CFU) (i.e.
Groups I, II, and III). (B) K-wire rolling experiments showed high S. aureus growth in
the animal groups inoculated with infected osteoblasts; no bacterial growth was observed
in the animal groups inoculated with PBS, osteoblasts, and a mixture of osteoblasts and
extracellular S. aureus (20 CFU).

81

Radiographic assessment of bone infection
No signs of infection were observed on post-operative day 21 in the radiographs
of rats (i.e. Groups I, II, and III) inoculated with PBS, osteoblasts, and osteoblasts
combined with 20 CFU of extracellular S. aureus (Fig. 4A); the X-ray images of these
animals were characterized by the formation of normal bridging calluses at the fracture
sites. By contrast, animal groups (i.e. Groups IV, V, and VI) inoculated with infected
osteoblasts (102 or 106 CFU) exhibited severe osteolysis on post-operative day 21.
Meanwhile, no severe osteolysis was observed on post-operative day 7 in the animals
inoculated with infected osteoblasts (Fig. 4B).

Figure 4 (A)

82

Figure 4 (B)
Figure. 4. (A) Radiographs of fractured femurs on post-operative day 21 presented
significant osteolysis in the animal groups inoculated with infected osteoblasts (i.e.
Groups IV, V, and VI) while normal bone healing was seen in the animal groups
inoculated with PBS, osteoblasts, and a mixture of osteoblasts and extracellular S. aureus
(20 CFU) (i.e. Groups I, II, and III). (B) Radiographs of fractured femurs on postoperative day 0, 7, and 21 did not show severe osteolysis in the rats inoculated with
infected osteoblasts (e.g. Group VI) on post-operative day 7.

Body weight and complete blood counts
A significant loss in body weight was observed in rat groups (i.e. Groups IV, V,
and VI) inoculated with infected osteoblasts (102 or 106 CFU of intracellular S. aureus)
compared to the animal groups (i.e. Groups I, II, and III) inoculated with PBS,
osteoblasts, and osteoblasts combined with 20 CFU of extracellular S. aureus (Fig. 5).
Interestingly, relatively more, although not significant, weight gain was seen on post-
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operative day 21 in the animal groups (i.e. Groups II and III) inoculated with osteoblasts

Percentage of weight change

compared to the group (i.e. Group I) inoculated with PBS (Fig. 5).
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Figure 5. Net weight loss of the rats on post-operative day 21 was significantly higher in
the animal groups inoculated with infected osteoblasts (i.e. Groups V, and VI) compared
to those in the animal groups inoculated with PBS, osteoblasts, and a mixture of
osteoblasts and extracellular S. aureus (20 CFU) (i.e. Groups I, II, and III). Data were an
average of six rats in each group.
The neutrophils in the blood of rat groups (i.e. Groups IV, V, and VI) inoculated
with infected osteoblasts (102 or 106 CFU) were significantly elevated on post-operative
day 21 compared to the animal groups (i.e. Groups I, II, and III) inoculated with PBS,
osteoblasts, and osteoblasts combined with 20 CFU of extracellular S. aureus (Fig. 6).
No significant differences (data not shown) were seen on post-operative day 21 in the
numbers of lymphocytes, monocytes, and eosinophils among all the animal groups
studied.
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Figure 6. Complete blood counts on post-operative day 21 showed that neutrophil
numbers were significantly higher in the animal groups inoculated with infected
osteoblasts (i.e. Groups IV, V, and VI) compared to those animal groups inoculated with
osteoblasts and a mixture of osteoblasts and extracellular S. aureus (20 CFU) (i.e. Groups
II and III).
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Discussion
S. aureus is a major human pathogen causing significant morbidity and mortality
in both community- and hospital-acquired infections. Surprisingly, S. aureus is frequently
successful in overcoming both host defense mechanisms and most antibiotic treatments,
was found among chronic and recurrent infections, and could be responsible for such
infections. This bacterium is believed to have developed several means to combat
conventional antibiotic therapies, among which are its ability to survive for long periods
of time inside host cells [14]. The purpose of the present study was to examine whether
intracellular S. aureus contributes to infection in vivo. Effort was taken to completely
eradicate extracellular S. aureus in the inoculums by treating them with gentamicin; the
complete killing of extracellular S. aureus was verified in our studies as well as by others
[15, 16, 19, 20]. Also, gentamicin remaining in the inoculum samples was expected to
eliminate any extracellular S. aureus that leaked out within the first few hours after
infection.
We investigated whether intracellular S. aureus within osteoblasts could induce
infection in our open femur fracture rat model. An open femur fracture model was used
because open fractures have high rates of infection and infection recurrence, and a high
rate of recurrence or relapse of infections was reported in traumatic extremity injuries (8,
9). We found that animals inoculated with S. aureus infected osteoblasts with
intracellular S. aureus CFU of 102 (i.e. Group IV) and 106 (i.e. Groups V and VI) all led
to severe infections. The results were confirmed by culturing bone and muscle specimens
from the fracture sites and explanted K-wires (Fig. 3) and visualizing via radiography of
the fractured bones (Fig. 4). Inoculation of intracellular S. aureus of 102 CFU led to the
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same degree of infection as 106 CFU inoculum, evidenced by approximately the same
CFU of bone or muscle specimens on post-operative day 21 (Fig. 3). Animals inoculated
with no bacteria (i.e. Groups I and II) or with 20 CFU of extracellular S. aureus (i.e.
Group III) did not exhibit infection on post-operative day 21. No systemic infection was
observed in any of the animal groups investigated because no CFU was found in blood
samples. These suggest that intracellular S. aureus of as low as 102 CFU within
osteoblasts induced bone infections in our rat open femur fracture model; the infection
was localized.
It was interesting that severe bone infections could be induced by intracellular S.
aureus within osteoblasts at a low rate of 102 CFU, which was the same quantity of
inoculum as our previous rat studies where 102 CFU of extracellular S. aureus was
sufficient to induce bone infections in our open fracture rat model [17, 18, 21]. This
suggested that not only extracellular but also intracellular S. aureus of as low as 102 CFU
could induce severe bone infections in open fractures. Note that inoculation of uninfected
osteoblasts did not have an effect on infection; no CFU was observed in corresponding
bone, muscle, and K-wire samples (Fig. 3). However, although not significant, increased
weight gain was observed with injection of uninfected osteoblasts compared to injection
of PBS (Fig. 5); the reason was unknown.
Meanwhile, neutrophils were significantly increased on post-operative day 21 in
the animal groups inoculated with infected osteoblasts. This finding might suggest that
neutrophils have played a deleterious role in infections induced by S. aureus infected
osteoblasts. In the literature, neutrophils may have a protective or a deleterious role in S.
aureus infection. On one hand, neutrophils have long been believed to provide significant
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host defense against S. aureus infection. This is mainly because patients who are
neutropenic or who have defects in neutrophil functions are more susceptible to S. aureus
infection, and total ablation of neutrophils in an experimental mouse model of S. aureusinduced septic arthritis led to decreased survival of the animals and increased bacteremia
[22]. On the other hand, increased neutrophils were also found to correlate with
decreased survival of mice and increased bacterial burden at the infection site [23, 24].
It is important to note that both in vitro and in vivo studies have shown that S.
aureus can internalize and survive within both phagocytic and non-phagocytic cells. In
vitro, S. aureus can invade and survive within polymorphonuclear neutrophils and
monocytes [25-27] and osteoblasts [28, 29]. Infected human osteoblasts were shown to
release viable S. aureus, which were able to re-infect new osteoblasts [28]. S. aureus can
also internalize and perhaps even replicate within bovine mammary epithelial cells, both
in cell lines and in primary culture [30, 31]. In vivo, intracellular S. aureus was found, in
limited cases, in animals and patients. In animal studies, S. aureus was found to be able to
internalize and survive in osteoblasts in chick embryos [32] and in bovine alveolar cells
isolated from milk of infected cows [33]. In patient studies, intracellular S. aureus was
found inside epithelium, glandular, and myofibroblastic cells in intranasal biopsy
specimens obtained, during infection symptom-free periods, in three patients with
recurrent rhinosinusitis [34]. Molecular typing proved the clonal relationship of the
patient-specific Staphylococci. Intracellular S. aureus was also found in surgical bone
specimens from a patient who had chronic and recurrent bone infection [35]. The
intracellular S. aureus appeared to be sequestered and protected from the host immune
system within the osteoblast or osteocyte cytoplasm for years [35]. In another case,
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intracellular S. aureus was cultured from five patients with persistent and recurrent
infections [36]. Alarmingly, some of those intracellular S. aureus were small-colony
variants which were non-hemolytic and non-pigmented, grew very slowly on routine
culture media, and were resistant to aminoglycosides under routine conditions.
Therefore, there is some in vitro and in vivo evidence supporting the potential role
of intracellular S. aureus in Staphylococci pathogenesis. However, there is no definitive
in vivo proof before this study showing that intracellular S. aureus is directly responsible
for or contributes to infections (e.g. chronic and recurrent infection).

The results

presented here are important because they have demonstrated, for the first time, that
intracellular S. aureus could induce infection in vivo. Bacteria (e.g. S. aureus) could
internalize and survive within host cells (e.g. osteoblast) and, after “hiding” for some
time period (could be up to years [35]), these quiescent bacteria could escape from the
infected host cells into the surrounding tissue and could be sufficient to initiate a
recurrence of symptomatic infection.
Taken together, the findings reported here present the first in vivo direct evidence
that intracellular S. aureus can induce bone infections and may be responsible for chronic
and recurrent infections. These findings also suggested that as low as 102 CFU of
intracellular S. aureus may induce severe bone infections in open fractures. These
findings may greatly advance our understanding of the pathogenesis of bone infections,
especially chronic and recurrent infections. The induction of bone infections by
intracellular S. aureus was studied in this work; however, the findings are expected to be
applicable to other infections/diseases and intracellular pathogens.
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CHAPTER 4
Effect of Interleukin 12 on the Killing of Intracellular Staphylococcus
aureus
Abstract
The proinflammatory cytokine IL-12 may play a critical role in host defense
against intracellular pathogens, including bacteria, viruses, and parasites. We have
previously demonstrated the ability of intracellular S. aureus to live inside macrophages,
which may explain the chronic and recurrent nature of Staphylococcal infections. The
aim of this study was to determine the effect of IL-12 on killing intracellular S. aureus by
macrophages. Splenic macrophages were isolated from rat spleens, infected, and treated
with IL-12 or IL-12 neutralized with anti-IL-12 antibody or without IL-12. IL-12
treatment was found to exhibit a dose-dependent relationship with intracellular S. aureus,
and resulted in significant reduction of intracellular S. aureus at IL-12 dosages of 250 and
2500 pg/mL. The enhancement of macrophage killing activity was most effective and
significant at post-infection 24 - 36 h. Meanwhile, significantly higher levels of IFN-γ
and IL-12 were released from infected macrophages treated with IL-12 compared to untreated cells. No significant changes in reactive oxygen species production were detected
between treated and un-treated macrophages at post-infection time 0 and 24 h. These
findings demonstrate that IL-12 can stimulate macrophages to be more potent in killing
intracellular S. aureus and could be an effective immunotherapeutic agent for preventing
and treating intracellular Staphylococcal infections.
Keywords: Intracellular pathogens, Interleukin 12, S. aureus, macrophages, cytokine
therapy.
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Introduction
Intracellular pathogens are known to be a strong inducer of type-1 immune
responses, which are characterized by the robust production of interleukin 12 (IL-12)
from innate phagocytes and interferon gamma (IFN-γ) from natural killer (NK) cells and
T-cells. Studies have shown that macrophages failed to be activated to kill intracellular
bacteria in mice treated with IL-12 or IFN-γ neutralizing antibodies [1-6].
IL-12 is produced mainly by antigen-presenting cells and acts to connect the
innate and acquired immunities by inducing differentiation of antigen-specific T-cells of
Th1 phenotype and the release of IFN-γ from activated T-cells and NK cells [7-10]. IFNγ is produced by T-cells and considered to play an important role in activating
macrophages, the ultimate effector cells in host defense against intracellular infection
[11, 12]. Studies have reported that macrophages can be competent cells regarding the
ability to respond to IL-12, which has led to the notion that this cytokine can induce
macrophage activation through an autocrine pathway [15, 16]. It has been shown that
macrophages express β1 and β2 chains from the IL-12 receptor (IL-12R) [16]. IL-12 has
also been involved in programming the macrophage response to lipopolysaccharide (LPS)
by up-regulating the production of TNF-α [17].
In this study, we investigated the effects of IL-12 on the bacterial killing capacity
of macrophages with intracellular S. aureus, and presented evidence to support the
antibacterial activity of IL-12 against intracellular S. aureus. The findings will extend our
understanding of the effects of IL-12 on macrophages and may offer insights into an
immunotherapeutic approach to control chronic and recurrent S. aureus infection.
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Materials and Methods
Reagents
Tryptic soy agar (TSA, w/5% sheep blood) plates, tryptic soy broth (TSB),
phosphate buffered saline (PBS), fetal bovine serum (FBS), 45% glucose solution, 7.5%
sodium bicarbonate, sodium pyruvate, and Tris-buffer were all obtained from Fisher
Scientific (Pittsburgh, PA). RPMI-1640 media were purchased from LONZA
(Walkersville, MD). 100 U/mL penicillin/100 mg/mL streptomycin solution, rat IL-12
p70 ELISA kit, rat IFN-γ ELISA kit, and recombinant rat IL-12 (IL-12) were from
Invitrogen (Carlsbad, CA). Gentamicin, Triton X-100, lysostaphin, and ammonium
chloride were obtained from Sigma (St. Louis, MO). Dichlorofluorescin diacetate
(H2DCF-DA) was from Life Technologies (Grand Island, NY). Rat anti-IL-12 antibody
was purchased from R & D Systems (Minneapolis, MN).
IL-12 bioactivity
The bioactivity of recombinant rat IL-12 used in this study was assessed based on
the ability of IL-12 to induce secretion of IFN-γ by macrophages. In brief, splenic
macrophages of (0.5-1)×107 cells/mL were cultured in a 96-well plate (Fisher Scientific,
Pittsburgh, PA) in RPMI-1640 supplemented with different doses (0, 1, 10, 100, and
1000 pg/mL) of recombinant rat IL-12 at 37oC in a 5% CO2 incubator. After 48 h of
culturing, the supernatant was collected for IFN-γ analysis using enzyme-linked
immunosorbent assay (ELISA) by measuring the optical density at 450 nm following the
manufacturer’s guidelines. IFN-γ levels were determined by comparison with a standard
curve. The results were expressed as mean ± SE and are presented in Figure 1, which
shows that the recombinant rat IL-12 studied was bioactive.
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Bacterial culture
S. aureus (ATCC 25923) obtained from the American Type Culture Collection
(ATCC, Manassas, VA). A fresh inoculum was prepared by suspending 5 colonies of S.
aureus, grown on a blood agar plate, in 5 mL TSB and incubating at 37oC for 18 h. After
incubation, the S. aureus inoculum was centrifuged at 3750 rpm for 15 min at 4oC and
washed once with 10 mL PBS to obtain (6-8)×108 colony forming units/mL or CFU/mL.
The bacteria pellet was then re-suspended in RPMI-1640 medium free from
streptomycin/penicillin and FBS.
Splenic macrophage isolation and culture
Splenic macrophages were obtained as described in (Figure 2). Spleens were
obtained from healthy adult Sprague Dawley rats, and cut into small pieces in a petri-dish,
and minced between the frosted ends of microscopic slides. The splenocyte suspension
was filtered through a 70 μm nylon cell strainer (Fisher Scientific), and centrifuged at
2500 rpm at 4oC for 5 min. The supernatant was subsequently aspirated and the red blood
cells were lysed with a 5 mL lysis buffer containing 0.17 M tris-buffer and 0.16 M
ammonium chloride for 10 min. The lysis process was stopped by adding RPMI-1640
media supplemented with penicillin/streptomycin, FBS, glucose, sodium bicarbonate, and
sodium pyruvate (this will be referred to as complete media). The splenocyte suspension
was then centrifuged again at 2500 rpm at 4oC for 5 min followed by aspiration of the
supernatant. The splenocyte pellet was washed once with complete RPMI-1640 media by
centrifugation then re-suspended in complete RPMI-1640 media to obtain (0.5-1)×107
cells/mL. Cell viability was determined by trypan-blue exclusion assay. Splenocytes were
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seeded in 48-well plate (Fisher Scientific) for 4 h and non-adherent cells (mainly B and
T-cells) were washed twice with PBS and adherent cells (primarily macrophages, and
referred to as splenic macrophages here) were further cultured in complete RPMI-1640
media and incubated in a 5% CO2 incubator at 37oC for 48 h.
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8

Figure 2. Steps for isolating splenic macrophages. (I) Rat spleens were collected in
RPMI-1640 complete media. (II) Spleens were cut into small pieces in petri-dish and
minced between the frosted ends of microscope glass slides to make a single cell
suspension. (III) and (IV) The cell suspension was filtered through a 70 μm cell strainer.
(V) Cells were collected by centrifugation at 2500 rpm and 4oC for 5 min. (VI) Cell
pellet was washed once with RPMI-1640 complete media and the pellet was obtained by
centrifugation. (VII) Red blood cells in the cell pellet were lysed with Tris-ammonium
chloride for 10 min and the lysis step was stopped by adding RPMI-1640 complete media.
(VIII) Cells were re-suspended in RPMI-1640 complete media for further culture.

Splenic macrophage infection and IL-12 treatment
Splenic macrophages of (0.5-1)×107 cells/mL were washed 3 times with PBS,
cultured with S. aureus at a multiplicity of infection (MOI) of 10:1 for 2 h, washed, and
incubated with gentamicin (100 μg/mL) for 2 h. The infected splenic macrophages were
first treated with different doses of recombinant rat IL-12 (0, 0.25, 2.5, 25, 250, and 2500
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pg/mL) in RPMI-1640 media supplemented with 5 μg/mL lysostaphin and 5% FBS for
24 h. The splenic macrophages were washed and lysed to determine the number of live
intracellular S. aureus by plating the lysates on blood agar plates. Next, the infected
splenic macrophages were treated with 250 pg/mL of IL-12 for different time periods (0,
12, 24, 36, and 48 h). The cell culture supernatants were collected for IFN-γ and IL-12
quantification using ELISA kits following the manufacturer’s guidelines; duplicates were
collected for each sample. The splenic macrophages were washed and lysed to determine
the number of live intracellular S. aureus. Data were presented as mean ± SE from at
least 3 different trials.

IL-12 bioactivity
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Figure 1. Quantitative measurement of bioactivity of IL-12 studied.

IL-12 action specificity
In order to further confirm the role of IL-12 treatment on infected splenic
macrophages, IL-12 was pre-treated with anti-IL-12 antibody and then added to infected
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splenic macrophages. As described in Chart 1, splenic macrophages of (0.5-1)×107
cells/mL were cultured, infected at an MOI of 10:1 for 2 h, incubated with gentamicin,
and washed. IL-12 of 250 pg/mL was neutralized with 0.1 μg/mL rat anti-IL-12 antibody
for 1 h at 37 C, and subsequently added to infected splenic macrophages and incubated
for 24 h. For comparison, infected splenic macrophages were also treated with or without
IL-12 of 250 pg/mL for 24 h. The cell culture supernatants were collected to determine
IFN-γ levels using an ELISA kit; duplicates were collected for each sample. The infected
splenic macrophages were washed with PBS and lysed to determine the number of
intracellular S. aureus.

Chart 1. A flowchart for testing IL-12 specificity by adding anti-IL-12 antibody (0.1
μg/mL) to neutralize IL-12 (250 pg/mL) biological activity for 1 h at 37oC.

Reactive oxygen species detection
Infected or non-infected splenic macrophages of (0.5-1)×107 cells/mL were
treated either with or without recombinant rat IL-12. At post-infection time 0 and 24 h,
cells were washed once with PBS and incubated with H2DCF-DA at 37 C for 1 h in the
dark. The fluorescence intensity was measured using a fluorescent microplate reader
(BioTek Instrument, Inc., Winooski, VT) at 492 nm/520 nm for 2',7'-dichlorofluorescein
(DCF), converted intracellularly from H2DCF-DA. The H2DCF-DA fluorescent probe is
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commonly used to detect reactive oxygen species. Data were average of six samples per
treatment.
Statistical analysis
All data were presented as means ± SE. Statistical significance was set at p < 0.05.
Statistical analysis was performed using GraphPad InStat Version 3.0 (GraphPad
Software Inco, La Jolla, CA).
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Results
Effect of IL-12 treatment on the survival of S. aureus within infected splenic macrophages
The S. aureus CFU within infected splenic macrophages decreased with
increasing IL-12 concentration in the range of 0-250 pg/mL, and was significantly lower
at IL-12 of 250 and 2500 pg/mL compared to the control (i.e. without IL-12 treatment)
(Figure 3A). The intracellular S. aureus CFU within infected splenic macrophages that
were treated with 250 and 2500 pg/mL of IL-12 was 18- and 14- fold lower than that of
the control, respectively. Meanwhile, the S. aureus CFU splenic macrophages also
decreased with increasing treatment time. The S. aureus CFU within splenic
macrophages that were treated with 250 pg/mL of IL-12 was significantly lower at 24 and
36 h compared to the corresponding controls without IL-12 treatment (Figure 3B).

Optimal dose of IL-12

S. aureus (CFU/mL)
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10 4

*

*

10 3
0

0.25
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25

250

2500

IL-12 (pg/mL)
Figure 3 (A). Intracellular S. aureus of infected splenic macrophages that were treated
with recombinant rat IL-12 at different doses (0, 0.25, 2.5, 25, 250, and 2500 pg/mL) for
24 h.
101

After blocking the activity of IL-12 using anti-IL-12, no significant differences
were observed in intracellular S. aureus CFU between infected splenic macrophages
without IL-12 treatment and splenic macrophages treated with antibody pre-treated IL-12
(Figure 3C).

Time course for IL-12 activity
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*
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12

24

*
36

Post-infection time (h)
Figure 3 (B). Intracellular S. aureus of infected splenic macrophages that were treated
with or without recombinant rat IL-12 of 250 pg/mL for different time periods (0, 12, 24,
and 36 h).

Effect of IL-12 treatment on cytokine production in infected splenic macrophages
Compared to cells without IL-12 treatment, infected splenic macrophages treated
with IL-12 had significantly higher IL-12 production at the post-infection times (i.e. 12,
24, 36, and 48 h) studied (Figure 4A). Similarly, a significant increase in IFNproduction was observed at the time periods investigated in IL-12 treated infected splenic
macrophages compared to the controls without IL-12 treatment (Figure 4B). At post102

infection 24 h, the IL-12 levels in the IL-12 treated cells and the controls were
approximately 427 and 324 pg/mL, respectively, and the IFN- levels in the IL-12 treated
cells and the controls were approximately 810 and 130 pg/mL, respectively.

S. aureus (CFU/mL)

10 6

10 5

10 4

10 3

*

no IL-12

IL-12

IL-12 Ab

Figure 3 (C). Comparison of intracellular S. aureus among infected splenic macrophages
treated with IL-12 (250 pg/mL), IL-12 (250 pg/mL) that was pre-treated with the anti-IL12 antibody, and without IL-12 for 24 h.
After blocking the activity of IL-12 using the anti-IL-12 antibody, no significant
differences were observed in IFN- levels between infected splenic macrophages without
IL-12 treatment and splenic macrophages treated with anti-IL-12 antibody pre-treated IL12 (Figure 4C).
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Figure 4 (A). IL-12 levels of infected splenic macrophages treated with or without IL-12
of 250 pg/mL for different time periods
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Figure 4 (B). IFN-γ levels of infected splenic macrophages treated with or without IL-12
of 250 pg/mL for different time periods.
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Figure 4 (C). Comparison of IFN-γ levels among infected splenic macrophages treated
with IL-12 (250 pg/mL), IL-12 (250 pg/mL) that was pre-treated with the anti-IL-12
antibody, and without IL-12 for 24 h.

Effect of IL-12 treatment on reactive oxygen species production in splenic macrophages
No significant differences in DCF levels were detected between IL-12 treated and
un-treated splenic macrophages at post-infection time 0 and 24 h (Figure 5).

DCF fluorescence intensity

Effect of IL-12 treatment on ROS production
60000

(-) IL-12
(+) IL-12

40000

20000

0
Control

Infected

Figure 5. DCF levels of infected and non-infected splenic macrophages that were treated
with or without IL-12 of 250 pg/mL for 24 h.
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Discussion
Killing of intracellular S. aureus may be critical for effective therapies to treat and
prevent chronic and recurrent Staphylococcal infections. In vivo, the control of
intracellular pathogens depends on the activation of Th1 immune responses, suggesting a
key role for macrophages. The importance of IL-12 production and subsequent IFN-γ
secretion to control intracellular bacteria has been demonstrated in multiple studies [4, 6,
19, 20]. However, few studies to date have examined the activity of IL-12 on macrophage
killing activity in vitro. Herein, we used an in vitro infection model of intracellular S.
aureus to examine the effect of IL-12 on the killing activity of splenic macrophages
against intracellular S. aureus.
We found that the intracellular killing activity of macrophages was enhanced with
IL-12 treatment, since the intracellular S. aureus CFU decreased with increasing IL-12
doses. Compared to the control without IL-12 treatment, significant differences were
observed at 250 and 2500 pg/mL (Figure 3A); and the best effective time span was found
to be between post-infection 24-36 h (Figure 3B). The enhancement of macrophage
killing activity by IL-12 treatment was further confirmed by neutralizing IL-12 with an
antibody specific to rat IL-12 where no significant differences were observed between
macrophages treated with and without IL-12 neutralized with anti-IL-12 antibody (Figure
3C). This finding was consistent with the observation that animals challenged with
bacteria and subsequently receiving treatment with anti-IL-12 antibody presented more
severe disease symptoms [4, 18]. Similarly, neutralizing IL-12 using the anti-IL-12
antibody increased morbidity in virus-infected mice compared with un-treated animals
[24]. By contrast, exogenous IL-12 was able to induce the activities of dendritic cells and
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cytotoxic T-cells against influenza virus infection when patients’ own antiviral immune
responses were poor [27, 26]. Exogenous IL-12 also rescued mice that were challenged
with a lethal dose of encephalomyocarditis virus through IFN-γ-mediated responses [25].
As a result, Orange and Coutelier suggested that low doses of IL-12 combined with
dendritic cells may be used as a potential immunotherapeutic approach against viral
infections [28, 29].
We further found that the enhancement of macrophage killing activity was
associated with the production of IL-12 and IFN- . Significantly higher levels of IL-12
and IFN- were detected in infected macrophages treated with IL-12 compared to
controls without IL-12 treatment (Figures 4A and 4B) while no significant differences
were observed in IFN- levels between macrophages treated with and without IL-12 that
was neutralized with anti-IL-12 antibody (Figure 4C). It was clear that exogenous IL-12
treatment resulted in significantly higher production of IFN- and IL-12 within infected
macrophages, which may reflect the notion that IL-12 could induce macrophage
activation through an autocrine pathway [15, 16]. Both IL-12 and IFN-γ were previously
found to be required for activating immune cells like macrophages during parasitic
infections, such as Leishmania major [30], by inducing Th1 differentiation and activating
macrophages to produce nitrogen oxide [31-33]. IL-12 also plays a critical role during the
early stages of viral infection by inducing NK cell cytotoxicity and IFN-γ production,
which leads to improved antimicrobial activity of phagocytic cells [27, 34-36].
Oxidative burst is one of the defense mechanisms used against pathogens, and
macrophages activated by IFN-γ were found to have increased release of nitric oxide
(NO) and reactive oxygen species (ROS) and enhanced bactericidal activities [13, 14].
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However, some bacteria such as Brucella, Salmonella, and Shigella can avoid inducing
oxidative burst when they encounter host cells (21, 22), and some bacteria like S. aureus
may express enzymes that can scavenge ROS species including O2- (23). In this study, no
significant differences in ROS levels were observed between macrophages treated with
and without IL-12 at post-infection time 0 and 24 h (Figure 5). This observation may
suggest an alternative killing activity than oxidative burst.

Conclusions
In this study, we examined the effect of IL-12 treatment on macrophage killing
activity in vitro by assessing the viable intracellular bacteria and cytokine as well as
reactive oxygen species production in infected splenic macrophages. We found that IL-12
treatment could significantly enhance the in vitro killing activity of macrophages and the
enhancement was dose and time dependent. Moreover, IL-12 treatment led to a
significant increase in IFN- and IL-12 production with no significant changes in ROS
production in infected macrophages compared to cells without IL-12 treatment. The
enhancement of macrophage killing activity by IL-12 was abolished when IL-12 was pretreated with the anti-IL-12 antibody.
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CHAPTER 5
General Discussion

Although S. aureus has been primarily considered an extracellular pathogen, it is
now clear that it can be internalized by both phagocytes and non-phagocytic cells.
Intracellular S. aureus is considered to play an important role in their persistence (host
defenses evasion) and recurrence (antibiotic failure) of infection.
The goal of my dissertation was to understand the invasion of S. aureus in
macrophages and osteoblasts and to explore potential prophylactic and therapeutic
interventions. The in vitro infection models demonstrate direct evidence for the ability of
S. aureus to be internalized by both phagocytic and non-phagocytic cells. Osteoblasts are
the most important cells for bone formation; therefore, any damage occurring to these
cells may result in disrupted bone homeostasis. Macrophages, on the other hand, are
important immune cells against invading pathogens and need to be fully efficient in
clearing bacteria in a short period of time. Our data have shown that S. aureus could
survive for several days within osteoblasts and macrophages, in the presence of
antibiotics. This time may be sufficient to induce phenotypic and genotypic changes in
the intracellular S. aureus which may make it harder to clear.
The success of the in vitro infection models has led us to examine the potential
that intracellular S. aureus alone could induce infection in an animal model. By
inoculating S. aureus infected osteoblasts, we found that intracellular S. aureus
inoculation of as low as 102 CFUs could induce severe bone infections in an open femur
fracture rat model.
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The role of IL-12 in intracellular pathogens’ clearance can be multifaceted. It is
well established that IL-12 stimulates IFN-γ in T-cells and NK cells. Also, IL-12 induces
CD4 Th cell differentiation toward a Th1 subset, and could have indirect, but more
widespread, effects within bone tissue. Our data have shown that IL-12 treatment has led
to a significant upgrade of IFN- production by infected macrophages and resulted in
significant reduction of intracellular S. aureus. As a result, IL-12 may be an innovative
therapeutic agent for eliminating intracellular S. aureus surviving within host cells.

Future Studies
According to the publication report from Web of Knowledge, there are very few
publications studying the pathogenesis of S. aureus infection in an in vitro co-culture
system which involves both osteoblasts and macrophages. Our data from Chapter 4
gives a promising future for IL-12 treatment in the presence of antibiotics to eliminate
intracellular S. aureus infection; therefore, studying the effect of IL-12 in a system where
both cell types (osteoblasts and macrophages) are present will provide a better model of
the actual situation.
Although our in vivo model is the first proof to directly link of the contribution of
intracellular S. aureus to cause bone infection; however, antibiotics were dismissed from
this model. In any clinical case of implant-associated infection, patients are treated with
antibiotics for at least 6 weeks following the surgery. A better model should be designed
to introduce antibiotics during the animal infection time to eliminate extracellular S.
aureus that leaks out from osteoblasts in the first several days.
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